1
|
Bu X, Zhao W, Zou H, Li W, Li M, Wang G. Immune response and apoptosis of gibel carp (Carassius auratus gibelio) gills to Chilodonella hexasticha infection: Insights from histopathological and multi-omics analyses. Fish Shellfish Immunol 2024; 147:109429. [PMID: 38342413 DOI: 10.1016/j.fsi.2024.109429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Revised: 02/01/2024] [Accepted: 02/04/2024] [Indexed: 02/13/2024]
Abstract
Gibel carp (Carassius auratus gibelio) is an important economically farmed fish in China. Chilodonella hexasticha parasitizes on the gills and fins of host fish, causing disruption to their normal respiration and movement, ultimately resulting in death of the fish. In this study, a combination of histopathological, immunohistochemical, transferase dUTP nick end labeling (TUNEL), multi-omics, and molecular approaches were employed to identify the immune reaction and cell apoptosis in gill tissue in response to C. hexasticha infection. Significant lamellae fusion, hyperplasia, hyperemia, necrosis, and desquamation of infected gibel carp gills were observed. In total, the expression of 3619 genes was higher, and 3143 lower, for gills in the infected group compared to the control group. Furthermore, 76 metabolites were significantly increased and 105 were significantly decreased in the infected group compared with the control group. From the qRT-PCR analysis results, immune system-related genes encoding IL-8, CXCL8a, and CXC11 were significantly up-regulated in infected gibel carp, while ZAP70 was significantly down-regulated. Immunohistochemical results also showed the down-regulated ZAP70 in the infected group. Apoptosis-related genes encoding CASP3 and Mcl-1b were up-regulated in response to C. hexasticha infection. These genes indicate the activation of CASP family-related apoptosis and Bim-mediated mitochondrial apoptotic pathways. TUNEL assays also revealed severe apoptosis in the infected group. Based on this study's results, it can be concluded that C. hexasticha infection leads to histopathological changes in the gills of infected fish, and induces both a significant immune response and apoptosis.
Collapse
Affiliation(s)
- Xialian Bu
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture (CAS), and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, Hubei, 430072, China; University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Weishan Zhao
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture (CAS), and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, Hubei, 430072, China
| | - Hong Zou
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture (CAS), and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, Hubei, 430072, China
| | - Wenxiang Li
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture (CAS), and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, Hubei, 430072, China
| | - Ming Li
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture (CAS), and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, Hubei, 430072, China.
| | - Guitang Wang
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture (CAS), and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, Hubei, 430072, China
| |
Collapse
|
2
|
Qin T, Hu G, Cheng J, Chen F, Fu P, Zhao W, Bu X, Cheng H, Zou H, Li W, Wu S, Wang G, Li M. Investigation of Ichthyophthirius multifiliis infection in fish from natural water bodies in the Lhasa and Nagqu regions of Tibet. Int J Parasitol Parasites Wildl 2024; 23:100894. [PMID: 38187442 PMCID: PMC10767491 DOI: 10.1016/j.ijppaw.2023.100894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Revised: 11/26/2023] [Accepted: 12/06/2023] [Indexed: 01/09/2024]
Abstract
This study aimed to examine the prevalence of Ichthyophthirius multifiliis in fish inhabiting natural water bodies in the Lhasa and Nagqu regions of Tibet in September 2020 and August 2021. The results showed that Schizopygopsis selincuoensis had the highest prevalence of I. multifiliis at 33.73% (56/166), followed by Triplophysa tibetana at 30.00% (6/20), Triplophysa brevicauda at 27.91% (12/43) and Schizopygopsis thermalis at 23.66% (31/131). No infection with I. multifiliis was observed in exotic fish species. In addition, the prevalence of I. multifiliis in Boqu Zangbo (river), Selincuo Lake and Cuona Lake in the Nagqu region was found to be significantly higher than that in Lalu Wetland and Chabalang Wetland in the Lhasa region (P < 0.05). The study revealed a significantly lower prevalence in Lhasa River than in Cuona Lake (P < 0.05). Notably, our findings revealed instances of I. multifiliis infections even in saline water bodies, thereby emphasizing the potential threat that this parasite poses to the preservation of indigenous fish resources in Tibet. Consequently, immediate and effective countermeasures are imperative. This study represents the first systematic investigation of I. multifiliis infection in natural water bodies in Tibet.
Collapse
Affiliation(s)
- Tian Qin
- Tibet University, Lhasa 850000, Tibet, China
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| | - Guangran Hu
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| | - Jiangwen Cheng
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| | - Fanglin Chen
- Tibet University, Lhasa 850000, Tibet, China
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| | - Peipei Fu
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| | - Weishan Zhao
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| | - Xialian Bu
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| | - Houda Cheng
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| | - Hong Zou
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| | - Wenxiang Li
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| | - Shangong Wu
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| | - Guitang Wang
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| | - Ming Li
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Laboratory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, Hubei, China
| |
Collapse
|
3
|
Zhao W, Xiong J, Li M, Bu X, Jiang C, Wang G, Zhang J, Li W, Zou H, Miao W, Chen K, Wang G. Genome assembly of a symbiotic balantidia (Balantidium ctenopharyngodoni) in fish hindgut. Sci Data 2024; 11:323. [PMID: 38548755 PMCID: PMC10978948 DOI: 10.1038/s41597-024-03142-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Accepted: 03/14/2024] [Indexed: 04/01/2024] Open
Abstract
Balantidium ctenopharyngodoni is identified as the sole ciliate species that exclusively resides within the hindgut of grass carp with high prevalence and intensity. In this study, the successful cultivation of B. ctenopharyngodoni enabled us to collect enough cells for genome sequencing. Consequently, we acquired a high-quality genome assembly spanning 68.66 Mb, encompassing a total of 22,334 nanochromosomes. Furthermore, we predicted 29,348 protein-coding genes, and 95.5% of them was supported by the RNA-seq data. The trend of GC content in the subtelomeric regions of single-gene chromosomes was similar to other ciliates containing nanochromosomes. A large number of genes encoding carbohydrate-binding modules with affinities for starch and peptidoglycans was identified. The identification of mitochondrion-related organelles (MROs) within genome indicates its well-suited adaptation to the anaerobic conditions in the hindgut environment. In summary, our results will offer resources for understanding the genetic basis and molecular adaptations of balantidia to hindgut of herbivorous fish.
Collapse
Affiliation(s)
- Weishan Zhao
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Protist 10,000 Genomics Project (P10K) Consortium, Wuhan, China
| | - Jie Xiong
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Protist 10,000 Genomics Project (P10K) Consortium, Wuhan, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
| | - Ming Li
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China.
- Protist 10,000 Genomics Project (P10K) Consortium, Wuhan, China.
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China.
| | - Xialian Bu
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Protist 10,000 Genomics Project (P10K) Consortium, Wuhan, China
| | - Chuanqi Jiang
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Protist 10,000 Genomics Project (P10K) Consortium, Wuhan, China
| | - Guangying Wang
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Protist 10,000 Genomics Project (P10K) Consortium, Wuhan, China
| | - Jing Zhang
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Protist 10,000 Genomics Project (P10K) Consortium, Wuhan, China
| | - Wenxiang Li
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
| | - Hong Zou
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
| | - Wei Miao
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Protist 10,000 Genomics Project (P10K) Consortium, Wuhan, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
| | - Kai Chen
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China.
- Protist 10,000 Genomics Project (P10K) Consortium, Wuhan, China.
| | - Guitang Wang
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China.
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China.
| |
Collapse
|
4
|
Zhao W, Bu X, Zhou W, Zeng Q, Qin T, Wu S, Li W, Zou H, Li M, Wang G. Interactions between Balantidium ctenopharyngodoni and microbiota reveal its low pathogenicity in the hindgut of grass carp. BMC Microbiol 2024; 24:7. [PMID: 38172646 PMCID: PMC10762984 DOI: 10.1186/s12866-023-03154-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2023] [Accepted: 12/11/2023] [Indexed: 01/05/2024] Open
Abstract
BACKGROUND Hosts, parasites, and microbiota interact with each other, forming a complex ecosystem. Alterations to the microbial structure have been observed in various enteric parasitic infections (e.g. parasitic protists and helminths). Interestingly, some parasites are associated with healthy gut microbiota linked to the intestinal eubiosis state. So the changes in bacteria and metabolites induced by parasite infection may offer benefits to the host, including protection from other parasitesand promotion of intestinal health. The only ciliate known to inhabit the hindgut of grass carp, Balantidium ctenopharyngodoni, does not cause obvious damage to the intestinal mucosa. To date, its impact on intestinal microbiota composition remains unknown. In this study, we investigated the microbial composition in the hindgut of grass carp infected with B. ctenopharyngodoni, as well as the changes of metabolites in intestinal contents resulting from infection. RESULTS Colonization by B. ctenopharyngodoni was associated with an increase in bacterial diversity, a higher relative abundance of Clostridium, and a lower abundance of Enterobacteriaceae. The family Aeromonadaceae and the genus Citrobacter had significantly lower relative abundance in infected fish. Additionally, grass carp infected with B. ctenopharyngodoni exhibited a significant increase in creatine content in the hindgut. This suggested that the presence of B. ctenopharyngodoni may improve intestinal health through changes in microbiota and metabolites. CONCLUSIONS We found that grass carp infected with B. ctenopharyngodoni exhibit a healthy microbiota with an increased bacterial diversity. The results suggested that B. ctenopharyngodoni reshaped the composition of hindgut microbiota similarly to other protists with low pathogenicity. The shifts in the microbiota and metabolites during the colonization and proliferation of B. ctenopharyngodoni indicated that it may provide positive effects in the hindgut of grass carp.
Collapse
Affiliation(s)
- Weishan Zhao
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
| | - Xialian Bu
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Weitian Zhou
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Qingwen Zeng
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Tian Qin
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Shangong Wu
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
| | - Wenxiang Li
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
| | - Hong Zou
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
| | - Ming Li
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China.
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China.
| | - Guitang Wang
- Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
- Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China
| |
Collapse
|
5
|
Bu X, Zhao W, Li W, Zou H, Li M, Wang G. Comparative Transcriptomics of Chilodonella hexasticha and C. uncinata Provide New Insights into Adaptations to a Parasitic Lifestyle and Mdivi-1 as a Potential Agent for Chilodonellosis Control. Int J Mol Sci 2023; 24:13058. [PMID: 37685862 PMCID: PMC10488290 DOI: 10.3390/ijms241713058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Revised: 08/09/2023] [Accepted: 08/16/2023] [Indexed: 09/10/2023] Open
Abstract
Chilodonella hexasticha is a harmful parasitic ciliate that can cause severe damage to fish and high mortalities worldwide. Its congeneric species, C. uncinata, is a facultative parasite that not only can be free-living but also can parasitize on fish gills and fins. In this study, single-cell transcriptomes of these two species were assembled and characterized. Numerous enzymes related to energy metabolism and parasitic adaption were identified through annotation in the Non-Redundant (NR), Clusters of Orthologous Genes (COG), Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. The expression of isocitrate dehydrogenase (IDH), cytochrome c oxidase subunit 1 (Cox1) and ATP synthase F1, delta subunit (ATP5D) was up-regulated in C. hexasticha compared with C. uncinata. The oxidative phosphorylation process was also enriched in C. hexasticha. The main mitochondrial metabolic pathways in C. hexasticha were depicted and enzymes related to energy metabolism pathways were compared between these two species. More importantly, mitochondrial division inhibitor 1 (mdivi-1) proved to be very effective in killing both C. hexasticha and C. uncinata, which could be a novel drug for Chilodonellosis control. This study can help us better understand the energy metabolisms of C. hexasticha and C. uncinata and provide new insight into novel targets for chilodonellosis control. Meanwhile, the transcriptome data can also facilitate genomic studies of these two species in the future.
Collapse
Affiliation(s)
- Xialian Bu
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Labatory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (X.B.); (W.Z.); (W.L.); (H.Z.); (G.W.)
- University of Chinese Academy of Sciences, Beijing 100049, China
- Protist 10,000 Genomics Project (P10K) Consortium, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China
| | - Weishan Zhao
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Labatory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (X.B.); (W.Z.); (W.L.); (H.Z.); (G.W.)
- Protist 10,000 Genomics Project (P10K) Consortium, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China
| | - Wenxiang Li
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Labatory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (X.B.); (W.Z.); (W.L.); (H.Z.); (G.W.)
| | - Hong Zou
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Labatory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (X.B.); (W.Z.); (W.L.); (H.Z.); (G.W.)
| | - Ming Li
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Labatory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (X.B.); (W.Z.); (W.L.); (H.Z.); (G.W.)
- Protist 10,000 Genomics Project (P10K) Consortium, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China
| | - Guitang Wang
- State Key Laboratory of Freshwater Ecology and Biotechnology, and Key Labatory of Aquaculture Disease Control, Ministry of Agriculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China; (X.B.); (W.Z.); (W.L.); (H.Z.); (G.W.)
| |
Collapse
|
6
|
Zhang H, Li Z, Zheng S, Zheng P, Liang X, Li Y, Bu X, Zou X. Range-aided drift-free cooperative localization and consistent reconstruction of multi-ground robots. IEEE Robot Autom Lett 2023. [DOI: 10.1109/lra.2023.3244721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Affiliation(s)
- H. Zhang
- State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - Z. Li
- State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - S. Zheng
- State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - P. Zheng
- State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - X. Liang
- State Key Laboratory of Microwave Imaging Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - Y. Li
- State Key Laboratory of Microwave Imaging Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - X. Bu
- State Key Laboratory of Microwave Imaging Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - X. Zou
- State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| |
Collapse
|
7
|
Zheng S, Li Z, Liu Y, Zhang H, Zheng P, Liang X, Li Y, Bu X, Zou X. UWB-VIO Fusion for Accurate and Robust Relative Localization of Round Robotic Teams. IEEE Robot Autom Lett 2022. [DOI: 10.1109/lra.2022.3208354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. Zheng
- State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - Z. Li
- State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - Y. Liu
- State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - H. Zhang
- State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - P. Zheng
- State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - X. Liang
- State Key Laboratory of Microwave Imaging Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - Y. Li
- State Key Laboratory of Microwave Imaging Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - X. Bu
- State Key Laboratory of Microwave Imaging Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| | - X. Zou
- State Key Laboratory of Transducer Technology, Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
| |
Collapse
|
8
|
Wu Y, Bu X, Ke Y, Sun H, Li J, Chen L, Cui W, He Y, Wu L. Insight into the Stereocontrol of DNA Polymerase‐Catalysed Reaction by Chiral Cobalt Complexes. Adv Synth Catal 2022. [DOI: 10.1002/adsc.202200786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Y. Wu
- College of Chemistry and Chemical Engineering Xi'an Shiyou University Xi'an 710065 People's Republic of China
| | - X. Bu
- School of Chemical Sciences University of Chinese Academy of Sciences Beijing 100049 People's Republic of China
| | - Y. Ke
- School of Chemical Sciences University of Chinese Academy of Sciences Beijing 100049 People's Republic of China
| | - H. Sun
- School of Chemistry and Chemical Engineering Shaanxi Normal University Xi'an 710065 People's Republic of China
| | - J. Li
- College of Chemistry and Chemical Engineering Xi'an Shiyou University Xi'an 710065 People's Republic of China
| | - L. Chen
- School of Chemical Sciences University of Chinese Academy of Sciences Beijing 100049 People's Republic of China
| | - W. Cui
- School of Chemical Sciences University of Chinese Academy of Sciences Beijing 100049 People's Republic of China
| | - Y. He
- School of Chemical Sciences University of Chinese Academy of Sciences Beijing 100049 People's Republic of China
| | - L. Wu
- School of Chemical Sciences University of Chinese Academy of Sciences Beijing 100049 People's Republic of China
- State Key Laboratory of Natural and Biomimetic Drugs School of Pharmaceutical Sciences Peking University Beijing 100191 People's Republic of China
| |
Collapse
|
9
|
Van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman R, Kameda H, Zeng X, Sui Y, Bu X, Pangan A, Wung P, Song IH. POS0306 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS REFRACTORY TO BIOLOGIC THERAPY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2518] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundUpadacitinib (UPA) was shown to be safe and effective through 2 years in patients (pts) with active ankylosing spondylitis (AS) naïve to biologic disease-modifying antirheumatic drugs (bDMARDs) in the pivotal phase 2/3 SELECT-AXIS 1 trial.1,2ObjectivesTo assess the efficacy and safety of UPA in pts with active AS with an inadequate response (IR) to bDMARDs.MethodsSELECT-AXIS 2 (NCT04169373) was conducted under a master protocol and includes two separate studies (one for AS bDMARD-IR and one for non-radiographic axial spondyloarthritis [nr-axSpA]). The AS bDMARD-IR study is a randomized, double-blind, placebo (PBO)-controlled, phase 3 trial that enrolled adults ≥18 years with AS who met modified New York criteria, had BASDAI and pt’s assessment of total back pain scores ≥4 (numeric rating scale 0–10) at study entry, and had an IR to one or two bDMARDs (TNF inhibitor or IL-17 inhibitor). Pts were randomized 1:1 to receive oral UPA 15 mg once daily (QD) or PBO during the 14-week (wk) double-blind treatment period. The primary endpoint was ASAS40 response at wk 14. Multiplicity-controlled secondary endpoints evaluated at wk 14 were improvements from baseline in disease activity (ASDAS [CRP], ASDAS ID [<1.3], ASDAS LDA [<2.1], BASDAI50, ASAS20, and ASAS PR), pain (total and nocturnal back pain), function (BASFI), objective measure of inflammation (SPARCC MRI score of the spine), spinal mobility (BASMI), enthesitis (MASES), and quality of life (ASQoL and ASAS HI). Non-responder imputation incorporating multiple imputation (NRI-MI) was used to handle intercurrent events and missing data for binary endpoints. Cochran-Mantel-Haenszel (CMH) test and mixed-effect model for repeated measures (MMRM) were used for analyzing binary and continuous endpoints, respectively. Treatment-emergent adverse events (TEAEs) assessed through wk 14 are reported for pts who had ≥1 dose of study drug.ResultsAll 420 randomized pts with active AS received assigned treatment (UPA 15 mg, n=211; PBO, n=209); 409 (97%) received study drug through wk 14. Baseline demographic and disease characteristics were generally similar between treatment groups and reflective of an active AS bDMARD-IR population (74% male; mean age 42.4 years; mean disease duration 7.7 years; 83% HLA-B27 positive; mean BASDAI 6.8). Significantly more pts achieved the primary endpoint of ASAS40 response at wk 14 with UPA vs PBO (45% vs 18%; P<0.0001; Figure 1); UPA showed onset of effect in ASAS40 as early as wk 4 (nominal P≤0.05). All multiplicity-controlled secondary endpoints met statistical significance for UPA vs PBO at wk 14 across multiple clinical domains of AS (P<0.0001; Figure 1). The rate of TEAEs was similar between treatment groups through wk 14 (UPA, 41%; PBO, 37%). TEAEs led to discontinuation in 3 (1.4%) pts treated with PBO and none with UPA. Serious infections occurred with UPA (2.4%) but not with PBO and included 4 events of COVID-19 and 1 event of uveitis. Additional events of uveitis were reported in 3 (1.4%) pts treated with PBO. Inflammatory bowel disease (IBD) occurred in 1 (0.5%) pt on UPA and none on PBO. No malignancy, major adverse cardiovascular events, venous thromboembolic events, or death were reported with UPA; 1 event of malignancy was observed with PBO.ConclusionUPA 15 mg QD was significantly more effective than PBO over 14 wks of treatment in pts with active AS and IR to bDMARDs. No new safety risks were identified with UPA compared with its known safety profile.3,4 These findings are consistent with and complementary to those of SELECT-AXIS 1 (bDMARD-naïve AS population),1,2 and support the use of UPA in pts with active AS, including those who had a previous IR to bDMARD therapy.References[1]van der Heijde D, et al. Arthritis Rheumatol. 2021;73(suppl 10).[2]van der Heijde D, et al. Lancet. 2019;394(10214):2108–2117.[3]Cohen SB, et al. ARD. 2021;80:304–311.[4]Burmester G, et al. Rheumatol Ther. 2021;1–19.AcknowledgementsAbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, review, and approval of the abstract. No honoraria or payments were made for authorship. Medical writing support was provided by Julia Zolotarjova, MSc, MWC, of AbbVie.Disclosure of InterestsDésirée van der Heijde Consultant of: AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, and UCB, Employee of: Director of Imaging Rheumatology BV, Xenofon Baraliakos Speakers bureau: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, and UCB, Consultant of: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB, and Werfen, Grant/research support from: AbbVie, Novartis, Joachim Sieper Speakers bureau: AbbVie, Janssen, Merck, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Merck, and Pfizer, Atul Deodhar Consultant of: AbbVie, Amgen, Aurinia, BMS, Celgene, GSK, Janssen, Lilly, MoonLake, Novartis, Pfizer, and UCB., Grant/research support from: AbbVie, GSK, Lilly, Novartis, Pfizer, and UCB, Robert Inman Consultant of: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and Sandoz, Grant/research support from: AbbVie, Amgen, and Janssen, Hideto Kameda Speakers bureau: AbbVie, Asahi-Kasei, BMS, Chugai, Eisai, Janssen, Lilly, Mitsubishi-Tanabe, Novartis, and Pfizer, Consultant of: AbbVie, Janssen, Lilly, Novartis, Sanofi, and UCB, Grant/research support from: AbbVie, Asahi-Kasei, Boehringer Ingelheim, Chugai, Eisai, and Mitsubishi-Tanabe, Xiaofeng Zeng: None declared, Yunxia Sui Shareholder of: May own AbbVie stock or options, Employee of: AbbVie, Xianwei Bu Shareholder of: May own AbbVie stock or options, Employee of: AbbVie, Aileen Pangan Shareholder of: May own AbbVie stock or options, Employee of: AbbVie, Peter Wung Shareholder of: May own AbbVie stock or options, Employee of: AbbVie, In-Ho Song Shareholder of: May own AbbVie stock or options, Employee of: AbbVie
Collapse
|
10
|
Mease PJ, Setty A, Papp K, Van den Bosch F, Tsuji S, Keiserman M, Bu X, Chen L, Mccaskill R, Mcdearmon-Blondell E, Wung P, Tillett W. POS1041 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC THERAPIES: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 2 STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundUpadacitinib (UPA), an oral Janus kinase (JAK) inhibitor, demonstrated efficacy and safety in patients (pts) with psoriatic arthritis (PsA) and prior inadequate response or intolerance to ≥1 biologic disease-modifying antirheumatic drug (bDMARD) at week (wk) 56 in the phase 3 SELECT-PsA 2 study.1ObjectivesTo evaluate the efficacy and safety of UPA at wk 104 from the ongoing long-term extension of SELECT-PsA 2.MethodsPts were randomized to UPA 15 mg (UPA15), UPA 30 mg (UPA30), or placebo (PBO) for 24 wks; PBO pts were then switched to UPA15 or UPA30. For continuous UPA treatment groups, efficacy endpoints at wk 104 were analyzed using non-responder imputation (NRI) and as observed (AO) (binary endpoints) or mixed-effect model repeated measures (MMRM) and AO (continuous endpoints). Treatment-emergent adverse events (TEAEs) were summarized for pts who received ≥1 dose of study drug using visit-based cut-off at wk 104.ResultsA total of 641 pts received ≥1 dose of study drug. At wk 104, 38.4% of all patients had discontinued study drug, with the highest discontinuation observed in patients randomized to PBO at baseline (all PBO: 46.7%). The most common reasons for discontinuation were lack of efficacy (UPA15: 12.3%, UPA30: 8.7%, all PBO: 21.7%) and adverse event (UPA15: 10.9%, UPA30: 13.3%, all PBO: 12.7%). The proportion of UPA pts that achieved ACR20/50/70, MDA, PASI75/90/100, and resolution of dactylitis and enthesitis were generally similar, or further improved, with 104 wks of treatment vs 56 wks1 (Table 1). Similarly, mean change from baseline in HAQ-DI, patient’s assessment of pain, BASDAI, and ASDAS was improved with UPA treatment. At 104 wks of therapy, clinical responses were largely similar with UPA15 and UPA30. Generally, safety data at wk 104 (Figure 1) were consistent with that reported at wk 56.1 Rates of serious infection, herpes zoster, hepatic disorder, anemia, neutropenia, lymphopenia, and CPK elevation remained numerically higher with UPA30 vs UPA15, while rates of malignancies, MACE, and VTE were similar for both UPA groups. One death was reported with UPA15 (unexplained due to lack of information; however, the patient had recently been diagnosed with ovarian cancer) and 2 with UPA30 (pancytopenia and COVID-19 pneumonia).Table 1.Efficacy Endpoints at Week 104EndpointUPA15 (n=211)UPA30 (n=218)Proportion of Pts (%)aNRIAONRIAOACR2055.580.354.681.8ACR5044.562.939.959.4ACR7023.232.221.631.5Minimal Disease Activity (MDA)29.441.333.949.3PASI75b47.769.852.781.1PASI90b37.755.244.367.8PASI100b23.135.435.955.6Resolution of enthesitis by LEIc39.867.837.568.4Resolution of dactylitis by LDId54.597.452.096.9Change from BLeMMRMAOMMRMAOHealth Assessment Questionnaire - Disability Index (HAQ-DI)-0.36-0.39-0.50-0.53Patient’s assessment of pain (numeric rating scale)-2.7-3.0-2.9-3.1Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)f-2.6-3.0-2.6-2.9Ankylosing Spondylitis Disease Activity Score (ASDAS)f-1.4-1.7-1.3-1.5ACR20/50/70, ≥20%/50%/70% improvement in American College of Rheumatology criteria; AO, as observed; BL, baseline; LDI, Leeds Dactylitis Index; LEI, Leeds Enthesitis Index; MMRM, mixed effect model repeated measurement; NRI, non-responder imputation; PASI75/90/100, ≥75%/90%/100% improvement in Psoriasis Area and Severity Index; pts, patients; UPA, upadacitinib.aData shown as NRI and AO for binary endpoints.bFor pts with psoriasis affecting ≥3% of body surface area at BL.cFor pts with LEI >0 at BL; resolution LEI=0.dFor pts with LDI >0 at BL; resolution LDI=0.eData shown as MMRM (LS mean) and AO (mean) for continuous endpoints.fFor pts with psoriatic spondylitis at BL.ConclusionIn PsA pts with prior inadequate response or intolerance to ≥1 bDMARD, clinical responses were maintained with UPA15 and UPA30 up to 2 years of treatment. No new safety signals were identified in this long-term extension.References[1]Mease PJ, et al. Rheumatol Ther. 2021;8:903-19.AcknowledgementsAbbVie and the authors thank the patients, study sites, and investigators who participated in this clinical trial (NCT03104374). AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Monica R.P. Elmore, PhD of AbbVie.Disclosure of InterestsPhilip J Mease Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squib, Celgene, Eli Lilly, Galapagos, Genentech, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squib, Celgene, Eli Lilly, Galapagos, Genentech, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squib, Celgene, Eli Lilly, Galapagos, Genentech, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Arathi Setty Shareholder of: Employee of AbbVie and may hold stock options, Employee of: Employee of AbbVie, Kim Papp Speakers bureau: AbbVie, Akros, Allergan, Almirall, Amgen, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, Genentech/Roche, Janssen, Kyowa Kirin, LEO, Meiji, MSD, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, Takeda, UCB, and Valeant, Consultant of: AbbVie, Akros, Allergan, Almirall, Amgen, Arcutis, Avillion, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, Genentech/Roche, GSK, Janssen, Kyowa Kirin, LEO, Meiji, MSD, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, Takeda, UCB, and Valeant, Grant/research support from: AbbVie, Akros, Allergan, Almirall, Amgen, Arcutis, Avillion, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, Genentech/Roche, GSK, Janssen, Kyowa Kirin, LEO, Meiji, MSD, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, Takeda, UCB, and Valeant, Filip van den Bosch Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, and UCB, Shigeyoshi Tsuji Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, and UCB, Consultant of: AbbVie, Eli Lilly, Janssen, Novartis, and UCB, Grant/research support from: AbbVie, Eli Lilly, Janssen, Novartis, and UCB, MAURO KEISERMAN Speakers bureau: AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Xianwei Bu Shareholder of: Employee of AbbVie and may hold stock options, Employee of: Employee of AbbVie, Liang Chen Shareholder of: Employee of AbbVie and may hold stock options, Employee of: Employee of AbbVie, Reva McCaskill Shareholder of: Employee of AbbVie and may hold stock options, Employee of: Employee of AbbVie, Erin McDearmon-Blondell Shareholder of: Employee of AbbVie and may hold stock options, Employee of: Employee of AbbVie, Peter Wung Shareholder of: Employee of AbbVie and may hold stock options, Employee of: Employee of AbbVie, William Tillett Speakers bureau: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Celgene, Eli Lilly, MSD, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Celgene, Eli Lilly, and Janssen
Collapse
|
11
|
Mease PJ, Lertratanakul A, Papp K, Van den Bosch F, Tsuji S, Dokoupilova E, Keiserman M, Bu X, Chen L, Mccaskill R, Zueger P, Mcdearmon-Blondell E, Pangan A, Tillett W. POS0196 UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Upadacitinib (UPA) is an oral Janus kinase inhibitor currently under evaluation for the treatment of psoriatic arthritis (PsA). Previous 24-week results from the SELECT-PsA 2 study in patients with PsA and prior inadequate response to ≥1 biologic disease-modifying antirheumatic drug (bDMARD) demonstrated UPA efficacy with a safety profile consistent with that observed in rheumatoid arthritis.1Objectives:To evaluate the 56-week efficacy and safety of UPA in the SELECT-PsA 2 study.Methods:Patients were randomized to 56 weeks of blinded treatment with UPA 15 or 30 mg once daily (QD), or placebo (PBO) switched to UPA 15 or 30 mg QD at Week 24. Efficacy endpoints included proportions of patients achieving 20/50/70% improvement in American College of Rheumatology (ACR) criteria (ACR20/50/70), 75/90/100% improvement in the Psoriasis Area and Severity Index (PASI75/90/100), resolution of dactylitis and enthesitis, and minimal disease activity (MDA). Non-responder imputation was used for missing data. Treatment-emergent adverse events (TEAEs) were summarized for events occurring while on UPA and ≤30 days after last dose (for those who discontinued).Results:Of 641 patients who received ≥1 dose of study drug, 74.7% completed 56 weeks of treatment. Clinical improvements based on the proportion of patients achieving ACR20/50/70 and MDA (Figure 1), PASI75/90/100, and resolution of dactylitis and enthesitis were generally maintained through 56 weeks of UPA treatment. Week 56 results for patients who switched from PBO to UPA at Week 24 had a similar trajectory to those for patients originally randomized to UPA. Overall, improvements observed with UPA 15 mg were similar to or approached those with UPA 30 mg over 56 weeks. Dose-dependent increases were observed for exposure-adjusted event rates (EAERs) of serious infections, herpes zoster (HZ), hepatic disorders, hematologic lab-related adverse events, and creatine phosphokinase (CPK) elevations, but not for exposure-adjusted incidence rates (EAIRs) of major adverse cardiovascular events (MACE), venous thromboembolic events (VTEs), or malignancies (Table 1). Generally, rates of TEAEs were lower with UPA 15 mg versus 30 mg.Conclusion:In patients with PsA and prior inadequate response to ≥1 bDMARD, UPA efficacy was maintained over 56 weeks with no new safety signals.References:[1]Mease PJ, et al. Ann Rheum Dis 2020. Epub ahead of print.Table 1.Safety through Week 56EventUPA 15 mg QD(n=290; PY=419.4)UPA 30 mg QD(n=308; PY=423.5)EAER, events/100 PY (95% CI)Infection89.7 (81.0–99.2)113.6 (103.9–124.2) Serious infection2.6 (1.5–4.7)6.1 (4.2–9.0) Opportunistic infectiona0.7 (0.2–2.2)0.9 (0.4–2.5) HZ3.8 (2.3–6.2)8.5 (6.1–11.8) Active TB00Gastrointestinal perforation (adjudicated)00Hepatic disorder4.8 (3.1–7.4)17.7 (14.1–22.2)Anemia2.1 (1.1–4.1)5.4 (3.6–8.2)Neutropenia1.0 (0.4–2.5)3.1 (1.8–5.3)Lymphopenia0.7 (0.2–2.2)2.4 (1.3–4.4)CPK elevation5.2 (3.5–8.0)8.7 (6.3–12.1)Renal dysfunction0.5 (0.1–1.9)0.2 (0.0–1.7)EAIR, n/100 PY (95% CI)NMSCb1.2 (0.5–2.9)1.0 (0.4–2.5)Malignancy other than NMSCc1.2 (0.5–2.9)1.2 (0.5–2.9)Lymphomad0.5 (0.1–1.9)0MACE (adjudicated)0.2 (0–1.7)0.2 (0–1.7)VTE (adjudicated)0.2 (0–1.7)0.2 (0–1.7)aExcludes TB and HZ. bUPA 15 mg: 4 cases of BCC and 1 case of SCC of the skin; UPA 30 mg: 3 cases of BCC and 3 cases of SCC of the skin. cUPA 15 mg: 2 cases of prostate cancer, and single cases of malignant melanoma, ovarian cancer, and rectal cancer; UPA 30 mg: single cases of basosquamous carcinoma (considered NMSC after medical review), malignant melanoma, oropharyngeal SCC, and rectal adenocarcinoma, as well as endometrial cancer and ovarian cancer (in the same patient). dUPA 15 mg: 2 events of treatment-emergent abnormal lymphocyte morphology; abnormal lymphocytes were not reported in subsequent laboratory testingBCC, basal cell carcinoma; CI, confidence interval; NMSC, non-melanoma skin cancer; PY, patient-years; SCC, squamous cell carcinoma; TB, tuberculosisAcknowledgements:AbbVie funded this study; contributed to its design; participated in data collection, analysis, and interpretation of the data; and participated in the writing, review, and approval of the abstract. No honoraria or payments were made for authorship. Medical writing support was provided by Russell Craddock, PhD, of 2 the Nth (Cheshire, UK), and was funded by AbbVie.Disclosure of Interests:Philip J Mease Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squib, Celgene, Eli Lilly, Galapagos, Genentech, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squib, Celgene, Eli Lilly, Galapagos, Genentech, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squib, Celgene, Eli Lilly, Galapagos, Genentech, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Apinya Lertratanakul Shareholder of: May own stock/shares in AbbVie, Employee of: Currently employed by AbbVie, Kim Papp Speakers bureau: AbbVie, Akros, Allergan, Almirall, Amgen, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, Genentech/Roche, Janssen, Kyowa Kirin, LEO, Meiji, MSD, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, Takeda, UCB, and Valeant, Consultant of: AbbVie, Akros, Allergan, Almirall, Amgen, Arcutis, Avillion, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, Genentech/Roche, GSK, Janssen, Kyowa Kirin, LEO, Meiji, MSD, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, Takeda, UCB, and Valeant, Grant/research support from: AbbVie, Akros, Allergan, Almirall, Amgen, Arcutis, Avillion, Bausch Health, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, Genentech/Roche, GSK, Janssen, Kyowa Kirin, LEO, Meiji, MSD, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, Takeda, UCB, and Valeant, Filip van den Bosch Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, and UCB, Shigeyoshi Tsuji Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, and UCB., Consultant of: AbbVie, Eli Lilly, Janssen, Novartis, and UCB., Grant/research support from: AbbVie, Eli Lilly, Janssen, Novartis, and UCB., Eva Dokoupilova Grant/research support from: AbbVie, Affibody AB, Eli Lilly, Galapagos, Gilead, GSK, Hexal AG, MSD, Novartis, Pfizer, R-Pharm, Sanofi-Aventis, and UCB, MAURO KEISERMAN Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Xianwei Bu Shareholder of: May own stock/shares in AbbVie, Employee of: Currently employed by AbbVie, Liang Chen Shareholder of: May own stock/shares in AbbVie, Employee of: Currently employed by AbbVie, Reva McCaskill Shareholder of: May own stock/shares in AbbVie, Employee of: Currently employed by AbbVie, Patrick Zueger Shareholder of: May own stock/shares in AbbVie, Employee of: Currently employed by AbbVie, Erin McDearmon-Blondell Shareholder of: May own stock/shares in AbbVie, Employee of: Currently employed by AbbVie, Aileen Pangan Shareholder of: May own stock/shares in AbbVie, Employee of: Currently employed by AbbVie, William Tillett Speakers bureau: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Celgene, Eli Lilly, MSD, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Celgene, Eli Lilly, and Janssen
Collapse
|
12
|
van Vollenhoven R, Takeuchi T, Aelion J, Chávez N, Mannucci Walter P, Singhal A, Swierkot J, Friedman A, Khan N, Li Y, Bu X, Klaff J, Strand V. POS0655 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 3-YEAR RESULTS FROM THE SELECT-EARLY STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Upadacitinib (UPA), an oral Janus kinase inhibitor, demonstrated significant improvements in signs, symptoms, and structural inhibition as monotherapy (mono) vs methotrexate (MTX) in MTX-naïve patients (pts) with rheumatoid arthritis (RA) through 48 weeks (wks).1Objectives:To report the efficacy and safety of UPA vs MTX mono up to 156 wks in pts with RA from the ongoing long-term extension (LTE) of the SELECT-EARLY trial.Methods:During the 48-wk double-blind study period, pts were randomized to UPA 15 or 30 mg once daily (QD) or MTX (titrated to 20 mg/wk by Wk 8). At Wk 26, pts who did not achieve Clinical Disease Activity Index (CDAI) remission (≤2.8) and had <20% improvement from baseline in tender or swollen joint count received blinded rescue therapy (addition of MTX for UPA groups and UPA 15 or 30 mg for MTX group). In the LTE, pts received open-label treatment once the last pt reached Wk 48. Efficacy assessments up to Wk 156 were summarized by randomized group and included American College of Rheumatology (ACR) responses, remission and low disease activity (LDA) measures, and change in modified Total Sharp Score (mTSS; up to 96 wks). Treatment-emergent adverse events (AEs) per 100 pt-years (PY) for pts on continuous mono were summarized through 156 wks. Non-responder imputation was used for binary endpoints for missing data and when pts received rescue therapy or prematurely discontinued the study drug.Results:Of 945 pts randomized and treated, 775 entered the LTE on study drug (including 57 rescued pts; MTX, 33; UPA 15 mg, 17; UPA 30 mg, 7). Overall, 161 (21%) pts discontinued during the LTE. At Wk 156, higher proportions of pts randomized to UPA achieved a 20/50/70% improvement in ACR response (ACR20/50/70), LDA, and remission vs MTX (Figure 1). Change from baseline in mTSS at Wk 96 favored UPA vs MTX (data not shown). Most AEs were numerically more frequent with UPA 30 mg. The overall rate of serious infection was numerically higher with UPA vs MTX (Table 1). Herpes zoster (HZ), neutropenia, non-melanoma skin cancer (NMSC), and creatine phosphokinase (CPK) elevation were more frequent with UPA vs MTX. Two active tuberculosis (TB) events were reported in each UPA arm; 3 adjudicated gastrointestinal (GI) perforation events were observed in the UPA 30 mg arm. Adjudicated major adverse cardiovascular events (MACEs) or venous thromboembolic events (VTEs) were comparable across treatment arms.Conclusion:UPA monotherapy showed sustained clinically meaningful responses including remission vs MTX through Wk 156 but higher rates of several AEs, including HZ, neutropenia, and CPK elevations; no new safety risks were observed compared with previous results.1,2References:[1]van Vollenhoven R, et al. Ann Rheum Dis 2019;78:376–7; 2. Cohen SB, et al. Ann Rheum Dis 2020;annrheumdis-2020-218510.Table 1.Safety overviewE/100 PY (95% CI)MTX mono(n=314; PY=601.9)UPA 15 mg QD mono(n=317; PY=703.4)UPA 30 mg QD mono(n=314; PY=687.6)Any AE240.2(228.0, 252.9)268.0(256.0, 280.4)292.5(279.8, 305.5)Any serious AE10.8 (8.3, 13.8)12.2 (9.8, 15.1)16.3 (13.4, 19.6)Any AE leading to discontinuation of study drug6.5 (4.6, 8.9)7.3 (5.4, 9.5)7.7 (5.8, 10.1)Any deatha0.7 (0.2, 1.7)0.9 (0.3, 1.9)1.0 (0.4, 2.1)Serious infection2.5 (1.4, 4.1)3.3 (2.1, 4.9)4.4 (2.9, 6.2)Opportunistic infection excluding TB and HZ0.2 (0.0, 0.9)0.1 (0.0, 0.8)0.3 (0.0, 1.1)HZ0.8 (0.3, 1.9)4.5 (3.1, 6.4)4.7 (3.2, 6.6)Active TB00.3 (0.0, 1.0)0.3 (0.0, 1.1)NMSC00.4 (0.1, 1.2)1.0 (0.4, 2.1)Malignancy other than NMSC1.0 (0.4, 2.2)0.6 (0.2, 1.5)1.2 (0.5, 2.3)Hepatic disorder14.1 (11.3, 17.5)12.5 (10.0, 15.4)15.0 (12.2, 18.2)GI perforationb000.4 (0.1, 1.3)Neutropenia2.2 (1.2, 3.7)4.5 (3.1, 6.4)5.7 (4.0, 7.8)CPK elevation1.8 (0.9, 3.3)7.7 (5.8, 10.0)15.4 (12.6, 18.6)MACEb0.3 (0.0, 1.2)0.4 (0.1, 1.2)0.6 (0.2, 1.5)VTEb0.3 (0.0, 1.2)0.4 (0.1, 1.2)0.6 (0.2, 1.5)Data were censored at the time of MTX or UPA addition for rescued ptsaIncludes treatment-emergent (≤30 days after the last dose of study drug) and non-treatment-emergent deaths. bAdjudicatedAcknowledgements:AbbVie funded this study; contributed to its design; participated in data collection, analysis, and interpretation of the data; and in the writing, review, and approval of the abstract. No honoraria or payments were made for authorship. Medical writing support was provided by Russell Craddock, PhD, of 2 the Nth (Cheshire, UK), and was funded by AbbVie.Disclosure of Interests:Ronald van Vollenhoven Speakers bureau: AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Galapagos, Gilead, GSK, Janssen, Pfizer, Sanofi, Servier, UCB, and Viela Bio, Consultant of: AbbVie, AstraZeneca, Biogen, Biotest, Bristol-Myers Squibb, Galapagos, Gilead, GSK, Janssen, Pfizer, Sanofi, Servier, UCB, and Viela Bio, Grant/research support from: Bristol-Myers Squibb, GSK, Eli Lilly, Pfizer, Roche, and UCB, Tsutomu Takeuchi Speakers bureau: AbbVie, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Gilead, Mitsubishi Tanabe, Novartis, Pfizer, and Sanofi, Consultant of: Astellas, Chugai, and Eli Lilly, Grant/research support from: AbbVie, Asahi Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Mitsubishi Tanabe, Nippon Kayaku, Shionogi, Takeda, and UCB, Jacob Aelion Grant/research support from: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos/Gilead, Genentech, GSK, Horizon, Janssen, Mallinckrodt, Nektar, Nichi-Iko, Novartis, Pfizer, Regeneron, Roche, Sanofi, Selecta, and UCB, Nilmo Chávez Speakers bureau: AbbVie, Janssen, and Pfizer, Consultant of: AbbVie, Janssen, and Pfizer, Grant/research support from: AbbVie, Galapagos, Gilead, Pfizer, and Sanofi, Pablo Mannucci Walter Consultant of: AbbVie, Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Genentech/Roche, GSK, Janssen, and UCB, Atul Singhal Consultant of: AbbVie, Aclaris, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Gilead, Idorsia, Novartis, Oscotec, Pfizer, Regeneron, Roche/Genentech, Sanofi, Selecta, Takeda, UCB, and Viela Bio, Grant/research support from: AbbVie, Aclaris, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Gilead, Idorsia, Novartis, Oscotec, Pfizer, Regeneron, Roche/Genentech, Sanofi, Selecta, Takeda, UCB, and Viela Bio, Jerzy Swierkot Speakers bureau: AbbVie, Accord, BMS, Janssen, MSD, Pfizer, Roche, Sandoz, and UCB, Consultant of: AbbVie, Accord, BMS, Janssen, MSD, Pfizer, Roche, Sandoz, and UCB, Grant/research support from: AbbVie, Accord, BMS, Janssen, MSD, Pfizer, Roche, Sandoz, and UCB, Alan Friedman Shareholder of: May own stock or options in AbbVie, Employee of: AbbVie, Nasser Khan Shareholder of: May own stocks or options in AbbVie, Employee of: AbbVie, Yihan Li Shareholder of: May own stocks or options in AbbVie, Employee of: AbbVie, Xianwei Bu Shareholder of: May own stocks or options in AbbVie, Employee of: AbbVie, Justin Klaff Shareholder of: May own stock or options in AbbVie, Employee of: AbbVie, Vibeke Strand Consultant of: AbbVie, Amgen, Arena, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Genentech/Roche, Gilead, GSK, Ichnos, Inmedix, Janssen, Kiniksa, MSD, Myriad Genetics, Novartis, Pfizer, Regeneron, Sandoz, Sanofi, Setpoint, and UCB
Collapse
|
13
|
Fleischmann R, Mysler E, Bessette L, Peterfy C, Durez P, Tanaka Y, Swierkot J, Khan N, Bu X, LI Y, Song IH. POS0087 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 3 YEARS FROM THE SELECT-COMPARE STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:In the SELECT-COMPARE study, the Janus kinase inhibitor, upadacitinib (UPA), demonstrated significant improvements in the signs and symptoms of rheumatoid arthritis (RA) when administered at 15 mg once daily (QD) on background methotrexate (MTX) compared with adalimumab (ADA) plus MTX at Week 12 that were maintained through 72 weeks in patients with prior inadequate response to MTX.1Objectives:To assess the long-term safety and efficacy of UPA vs ADA over 3 years in the ongoing long-term extension (LTE).Methods:Patients receiving background MTX were randomized 2:2:1 to UPA 15 mg QD, placebo (PBO), or ADA 40 mg every other week. Between Weeks 14-26, rescue was mandated for either lack of response (<20% improvement in tender or swollen joint counts: Weeks 14, 18, 22) or failure to achieve a targeted disease outcome (CDAI low disease activity: Week 26). Patients who completed the 48-week double-blind period could enter an LTE for up to 10 years total. This analysis describes patients through 3 years of treatment. Treatment-emergent adverse events (TEAEs) per 100 patient years (PY), including events of special interest (AESI), were summarized up to 3 years based on exposure to UPA and to ADA. Efficacy was analyzed by original randomized groups. Patients who were rescued or prematurely discontinued study drug were categorized as non-responders for visits after rescue or discontinuation. Descriptive analyses were performed without formal statistical comparisons.Results:In total, 651, 651, and 327 patients were randomized at baseline to receive UPA, PBO, and ADA, respectively. Between Weeks 14-26, 252 (39%) patients were rescued from UPA to ADA, 159 (49%) were rescued from ADA to UPA, and all PBO patients were switched to UPA by Week 26.1 A higher proportion of patients randomized to UPA completed 3 years without rescue compared to those randomized to ADA (47% vs 36%, respectively). UPA was generally well-tolerated as assessed by the rates of TEAEs, including serious AEs, AEs leading to discontinuation of study drug, and AESIs, including serious and opportunistic infections, malignancies, adjudicated major adverse cardiac events or venous thromboembolism; Figure 1). Consistent with previous analyses, the event rates of AESIs were generally comparable between the UPA and ADA groups, while herpes zoster, lymphopenia, hepatic disorder, and CPK elevation were reported at higher rates with UPA. Consistent with earlier time points, greater proportions of patients randomized to UPA achieved low disease activity and remission at 3 years based on CDAI, as well as DAS28(CRP) ≤3.2 or <2.6, compared with patients randomized to ADA (Table 1).Conclusion:The safety profile of UPA was consistent with the results reported previously and with the integrated Phase 3 safety analysis.1,2 Higher levels of clinical response continued to be observed with UPA vs ADA through 3 years of treatment.References:[1]Fleischmann R, et al. Ann Rheum Dis 2020;79:323.[2]Cohen SB, et al. Ann Rheum Dis 2020; doi: 10.1136/annrheumdis-2020-218510.Table 1.Efficacy Endpoints at 3 Years (NRI)Endpoints, % (95% CI)UPA 15 mg QDN=651*ADA 40 mg EOWN=327*CDAI ≤1039 (36, 43)29 (24, 34)CDAI ≤2.824 (21, 28)17 (12, 21)DAS28(CRP) ≤3.237 (33, 41)26 (21, 31)DAS28(CRP) <2.632 (29, 36)22 (17, 26)ADA, adalimumab; CI, confidence interval; DAS28(CRP), Disease Activity Score for 28-joints C-Reactive Protein; CDAI, clinical disease activity index; EOW, every other week; NRI, non-responder imputation; QD, once daily; UPA, upadacitinib.*Patients who were rescued prior to/at Week 26 were considered non-responders. 252/651 and 159/327 patients were rescued of those randomized to UPA and ADA, respectively.Acknowledgements:AbbVie and the authors thank the patients, trial sites, and investigators who participated in this clinical trial. AbbVie, Inc was the trial sponsor, contributed to trial design, data collection, analysis & interpretation, and to writing, reviewing, and approval of final version. No honoraria or payments were made for authorship. The authors thank Dr. Tim Shaw of AbbVie Inc. for his support with the interpretation of the data. Medical writing support was provided by Ramona Vladea, PhD, of AbbVie, Inc.Disclosure of Interests:Roy Fleischmann Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen, Novartis, Pfizer Inc, Sanofi-Aventis, and UCB, Grant/research support from: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Janssen, Novartis, Pfizer Inc, Regeneron, Roche, Sanofi-Aventis and UCB, Eduardo Mysler Consultant of: AbbVie, AstraZeneca, Lilly, Pfizer, Roche, BMS, Sandoz, GSK, Janssen, Grant/research support from: AbbVie, AstraZeneca, Lilly, Pfizer, Roche, BMS, Sandoz, GSK, Janssen, Louis Bessette Consultant of: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Eli Lilly, Novartis, Gilead, Grant/research support from: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Eli Lilly, Novartis, Gilead, Charles Peterfy Shareholder of: Spire Sciences, Inc, Speakers bureau: Amgen, Bristol-Myers Squibb, Consultant of: Aclaris, Centrexion, Daiichi Sankyo, EMD, Serono, Five Prime, Flexion Therapeutics, Genentech, Gilead, GlaxoSmithKline, Istresso, Eli Lilly, Myriad Genetics, Novartis, Roche, SetPoint, Sorrento, UCB, Employee of: Spire Sciences, Inc, Patrick Durez Speakers bureau: BMS, Sanofi, Eli Lilly, Celltrion, Yoshiya Tanaka Speakers bureau: Daiichi-Sankyo, Astellas, Chugai, Eli Lilly, Pfizer, AbbVie, YL Biologics, Bristol-Myers, Takeda, Mitsubishi-Tanabe, Novartis, Eisai, Janssen, Teijin, Consultant of: Daiichi-Sankyo, Astellas, Chugai, Eli Lilly, Pfizer, AbbVie, YL Biologics, Bristol-Myers, Takeda, Mitsubishi-Tanabe, Novartis, Eisai, Janssen, Teijin, Grant/research support from: Asahi-kasei, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers, UCB, Daiichi-Sankyo, Eisai, Ono, Jerzy Swierkot Speakers bureau: AbbVie, Sandoz, Pfizer, Roche, BMS, UCB, MSD, Accord, Janssen, Consultant of: AbbVie, Sandoz, Pfizer, Roche, BMS, UCB, MSD, Accord, Janssen, Grant/research support from: AbbVie, Sandoz, Pfizer, Roche, BMS, UCB, MSD, Accord, Janssen, Nasser Khan Shareholder of: AbbVie, Employee of: AbbVie, Xianwei Bu Shareholder of: AbbVie, Employee of: AbbVie, Yihan Li Shareholder of: AbbVie, Employee of: AbbVie, In-Ho Song Shareholder of: AbbVie, Employee of: AbbVie.
Collapse
|
14
|
Coates LC, Tillett W, D’agostino MA, Rahman P, Behrens F, Conaghan PG, Mcdearmon-Blondell E, Bu X, Chen L, Kapoor M, Mease PJ. OP0050 ADALIMUMAB INTRODUCTION VERSUS METHOTREXATE DOSE ESCALATION IN PATIENTS WITH INADEQUATELY CONTROLLED PSORIATIC ARTHRITIS: RESULTS FROM RANDOMIZED PHASE 4 CONTROL STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2393] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Methotrexate (MTX) is often used as first-line therapy for patients (pts) with psoriatic arthritis (PsA) despite limited efficacy and data on appropriate dosage. Minimal Disease Activity (MDA) is suggested as an optimal treat-to-target outcome. Biologic disease-modifying antirheumatic drugs (bDMARDs) have demonstrated improved outcomes (including MDA rates) over MTX. However, more data are needed to define the optimal timing of bDMARD initiation and characterize efficacy of MTX dose escalation, to achieve optimal outcomes.Objectives:To compare achievement of MDA between adding adalimumab (ADA) vs escalating MTX dose in PsA pts with inadequate disease control after initial MTX therapy.Methods:The open-label, 2-part CONTROL study enrolled bDMARD-naive adult pts with active PsA (not in MDA at screening and ≥3 tender and ≥3 swollen joints) despite MTX 15 mg every wk (ew) for ≥4 wks. Pts were randomized to ADA 40 mg every other wk + MTX 15 mg (ADA+MTX) or escalated MTX to 20–25 mg ew or highest tolerable dose during 16-wk part 1 (Fig 1). The primary endpoint was achievement of MDA, defined as fulfilling ≥5 of the 7 criteria: tender joint count 68 (TJC68) ≤1, swollen joint count 66 (SJC66) ≤1, Psoriasis Area Severity Index (PASI) ≤1 or body surface area (BSA) ≤3%, pt’s pain (visual analogue scale [VAS] 0–100) ≤15, Pt’s Global Assessment of disease activity (PtGA) VAS ≤20, Health Assessment Questionnaire Disability Index (HAQ-DI) ≤0.5 and tender entheseal points (0–8) ≤1. Key secondary efficacy endpoints were achievement of ACR20 and PASI75 and change from baseline in HAQ-DI and Leeds Enthesitis Index (LEI) at wk 16.Results:Overall, 246 pts were randomized; 245 received treatment (ADA+MTX, n=123; escalated MTX, n=122); 117 (95%) pts and 110 (90%) pts, respectively, completed part 1. Baseline characteristics were similar between groups (Table). During part 1, the average dose of MTX was 21.8 mg/wk (55% on oral MTX) in the escalated MTX group. Significantly higher proportion of pts in ADA+MTX (42%) vs escalated MTX (13%) group achieved MDA at wk 16 (non-responder imputation [NRI]; difference [95% CI] 28% [18%–39%];P<0.001;Fig 2). Observed case analysis confirmed the NRI analysis. Lower MDA rates at wk 16 were observed in the escalated MTX arm regardless of prior MTX duration (Fig 2). Significant improvements in key secondary endpoints were also observed with ADA+MTX vs escalated MTX (allP<0.05;Fig 2). In part 1, the proportion of patients with adverse events was similar between groups (ADA+MTX, 62% vs escalated MTX, 57%); no opportunistic infections, tuberculosis, malignancies, or deaths were reported during part 1.Conclusion:A significantly higher proportion of pts achieved MDA at wk 16 after introducing ADA compared with escalating MTX dose; higher rates were observed regardless of prior MTX duration. Significantly higher responses in musculoskeletal, skin, and quality of life measures were observed with ADA+MTX vs escalated MTX. No new safety signals with ADA were identified in this pt population.Table 1.Baseline DemographicsCharacteristics, mean (SD)ADA+MTXn=123Escalated MTXn=122Female, n (%)64 (52.0)59 (48.4)Age, y51.4 (12.2)48.8 (12.7)BSA >3%, n (%)74 (60.2)78 (63.9)Pt pain63.7 (19.5)62.3 (20.9)PtGA65.0 (19.9)62.9 (20.9)HAQ-DI1.2 (0.6)1.2 (0.7)LEI + plantar count3.5 (2.1)3.5 (2.1)Disclosure of Interests:Laura C Coates: None declared, William Tillett Grant/research support from: AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, Consultant of: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, MSD, Pfizer Inc, UCB, Speakers bureau: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, Pfizer Inc, UCB, Maria Antonietta D’Agostino Consultant of: AbbVie, BMS, Novartis, and Roche, Speakers bureau: AbbVie, BMS, Novartis, and Roche, Proton Rahman Grant/research support from: Janssen and Novartis, Consultant of: Abbott, AbbVie, Amgen, BMS, Celgene, Lilly, Janssen, Novartis, and Pfizer., Speakers bureau: Abbott, AbbVie, Amgen, BMS, Celgene, Lilly, Janssen, Novartis, Pfizer, Frank Behrens Grant/research support from: Pfizer, Janssen, Chugai, Celgene, Lilly and Roche, Consultant of: Pfizer, AbbVie, Sanofi, Lilly, Novartis, Genzyme, Boehringer, Janssen, MSD, Celgene, Roche and Chugai, Philip G Conaghan Consultant of: AbbVie, BMS, Eli Lilly, EMD Serono, Flexion Therapeutics, Galapagos, GSK, Novartis, Pfizer, Speakers bureau: AbbVie, Eli Lilly, Novartis, Pfizer, Erin McDearmon-Blondell Shareholder of: AbbVie, Employee of: AbbVie, Xianwei Bu Shareholder of: AbbVie, Employee of: AbbVie, Liang Chen Shareholder of: AbbVie, Employee of: AbbVie, Mudra Kapoor Shareholder of: AbbVie, Employee of: AbbVie, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau
Collapse
|
15
|
Chu D, Zhang J, Bu X, Dang C, Wang W, Zhang Z. Body mass index, tumour location, and colorectal cancer survival. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz421.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Chu D, Zhang Z, Zhang J, Wang Y, Li Y, Bu X, Li E, Zhang J. Positive feedback activation of notch signal by obesity enhances colorectal tumorigenicity. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz269.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Adamson P, Ader C, Andrews M, Anfimov N, Anghel I, Arms K, Arrieta-Diaz E, Aurisano A, Ayres DS, Backhouse C, Baird M, Bambah BA, Bays K, Bernstein R, Betancourt M, Bhatnagar V, Bhuyan B, Bian J, Biery K, Blackburn T, Bocean V, Bogert D, Bolshakova A, Bowden M, Bower C, Broemmelsiek D, Bromberg C, Brunetti G, Bu X, Butkevich A, Capista D, Catano-Mur E, Chase TR, Childress S, Choudhary BC, Chowdhury B, Coan TE, Coelho JAB, Colo M, Cooper J, Corwin L, Cronin-Hennessy D, Cunningham A, Davies GS, Davies JP, Del Tutto M, Derwent PF, Deepthi KN, Demuth D, Desai S, Deuerling G, Devan A, Dey J, Dharmapalan R, Ding P, Dixon S, Djurcic Z, Dukes EC, Duyang H, Ehrlich R, Feldman GJ, Felt N, Fenyves EJ, Flumerfelt E, Foulkes S, Frank MJ, Freeman W, Gabrielyan M, Gallagher HR, Gebhard M, Ghosh T, Gilbert W, Giri A, Goadhouse S, Gomes RA, Goodenough L, Goodman MC, Grichine V, Grossman N, Group R, Grudzinski J, Guarino V, Guo B, Habig A, Handler T, Hartnell J, Hatcher R, Hatzikoutelis A, Heller K, Howcroft C, Huang J, Huang X, Hylen J, Ishitsuka M, Jediny F, Jensen C, Jensen D, Johnson C, Jostlein H, Kafka GK, Kamyshkov Y, Kasahara SMS, Kasetti S, Kephart K, Koizumi G, Kotelnikov S, Kourbanis I, Krahn Z, Kravtsov V, Kreymer A, Kulenberg C, Kumar A, Kutnink T, Kwarciancy R, Kwong J, Lang K, Lee A, Lee WM, Lee K, Lein S, Liu J, Lokajicek M, Lozier J, Lu Q, Lucas P, Luchuk S, Lukens P, Lukhanin G, Magill S, Maan K, Mann WA, Marshak ML, Martens M, Martincik J, Mason P, Matera K, Mathis M, Matveev V, Mayer N, McCluskey E, Mehdiyev R, Merritt H, Messier MD, Meyer H, Miao T, Michael D, Mikheyev SP, Miller WH, Mishra SR, Mohanta R, Moren A, Mualem L, Muether M, Mufson S, Musser J, Newman HB, Nelson JK, Niner E, Norman A, Nowak J, Oksuzian Y, Olshevskiy A, Oliver J, Olson T, Paley J, Pandey P, Para A, Patterson RB, Pawloski G, Pearson N, Perevalov D, Pershey D, Peterson E, Petti R, Phan-Budd S, Piccoli L, Pla-Dalmau A, Plunkett RK, Poling R, Potukuchi B, Psihas F, Pushka D, Qiu X, Raddatz N, Radovic A, Rameika RA, Ray R, Rebel B, Rechenmacher R, Reed B, Reilly R, Rocco D, Rodkin D, Ruddick K, Rusack R, Ryabov V, Sachdev K, Sahijpal S, Sahoo H, Samoylov O, Sanchez MC, Saoulidou N, Schlabach P, Schneps J, Schroeter R, Sepulveda-Quiroz J, Shanahan P, Sherwood B, Sheshukov A, Singh J, Singh V, Smith A, Smith D, Smolik J, Solomey N, Sotnikov A, Sousa A, Soustruznik K, Stenkin Y, Strait M, Suter L, Talaga RL, Tamsett MC, Tariq S, Tas P, Tesarek RJ, Thayyullathil RB, Thomsen K, Tian X, Tognini SC, Toner R, Trevor J, Tzanakos G, Urheim J, Vahle P, Valerio L, Vinton L, Vrba T, Waldron AV, Wang B, Wang Z, Weber A, Wehmann A, Whittington D, Wilcer N, Wildberger R, Wildman D, Williams K, Wojcicki SG, Wood K, Xiao M, Xin T, Yadav N, Yang S, Zadorozhnyy S, Zalesak J, Zamorano B, Zhao A, Zirnstein J, Zwaska R. First Measurement of Electron Neutrino Appearance in NOvA. Phys Rev Lett 2016; 116:151806. [PMID: 27127961 DOI: 10.1103/physrevlett.116.151806] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Indexed: 06/05/2023]
Abstract
We report results from the first search for ν_{μ}→ν_{e} transitions by the NOvA experiment. In an exposure equivalent to 2.74×10^{20} protons on target in the upgraded NuMI beam at Fermilab, we observe 6 events in the Far Detector, compared to a background expectation of 0.99±0.11(syst) events based on the Near Detector measurement. A secondary analysis observes 11 events with a background of 1.07±0.14(syst). The 3.3σ excess of events observed in the primary analysis disfavors 0.1π<δ_{CP}<0.5π in the inverted mass hierarchy at the 90% C.L.
Collapse
Affiliation(s)
- P Adamson
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - C Ader
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M Andrews
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - N Anfimov
- Joint Institute for Nuclear Research Joliot-Curie, 6 Dubna, Moscow Region 141980, Russia
| | - I Anghel
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - K Arms
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - E Arrieta-Diaz
- Department of Physics, Southern Methodist University, Dallas, Texas 75275, USA
| | - A Aurisano
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - D S Ayres
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - C Backhouse
- California Institute of Technology, Pasadena, California 91125, USA
| | - M Baird
- Indiana University, Bloomington, Indiana 47405, USA
| | - B A Bambah
- School of Physics, University of Hyderabad, Hyderabad 500 046, India
| | - K Bays
- California Institute of Technology, Pasadena, California 91125, USA
| | - R Bernstein
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M Betancourt
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - V Bhatnagar
- Department of Physics, Panjab University, Chandigarh 106 014, India
| | - B Bhuyan
- Department of Physics, IIT Guwahati, Guwahati 781 039, India
| | - J Bian
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - K Biery
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - T Blackburn
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - V Bocean
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Bogert
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Bolshakova
- Joint Institute for Nuclear Research Joliot-Curie, 6 Dubna, Moscow Region 141980, Russia
| | - M Bowden
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - C Bower
- Indiana University, Bloomington, Indiana 47405, USA
| | - D Broemmelsiek
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - C Bromberg
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - G Brunetti
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - X Bu
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Butkevich
- Institute for Nuclear Research of Russian Academy of Sciences, 7a 60th October Anniversary Prospect, Moscow 117312, Russia
| | - D Capista
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - E Catano-Mur
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - T R Chase
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - S Childress
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - B C Choudhary
- Department of Physics & Astrophysics, University of Delhi, Delhi 110007, India
| | - B Chowdhury
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - T E Coan
- Department of Physics, Southern Methodist University, Dallas, Texas 75275, USA
| | - J A B Coelho
- Department of Physics and Astonomy, Tufts University, Medford, Massachusetts 02155, USA
| | - M Colo
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - J Cooper
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - L Corwin
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - D Cronin-Hennessy
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - A Cunningham
- Physics Department, University of Texas at Dallas, 800 W. Campbell Road, Richardson, Texas 75083-0688, USA
| | - G S Davies
- Indiana University, Bloomington, Indiana 47405, USA
| | - J P Davies
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - M Del Tutto
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - P F Derwent
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K N Deepthi
- School of Physics, University of Hyderabad, Hyderabad 500 046, India
| | - D Demuth
- Math, Science and Technology Department, University of Minnesota-Crookston, Crookston, Minnesota 56716, USA
| | - S Desai
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - G Deuerling
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Devan
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - J Dey
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R Dharmapalan
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - P Ding
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S Dixon
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - Z Djurcic
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - E C Dukes
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Duyang
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - R Ehrlich
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - G J Feldman
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - N Felt
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - E J Fenyves
- Physics Department, University of Texas at Dallas, 800 W. Campbell Road, Richardson, Texas 75083-0688, USA
| | - E Flumerfelt
- Department of Physics and Astronomy, University of Tennessee, 1408 Circle Drive, Knoxville, Tennessee 37996, USA
| | - S Foulkes
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M J Frank
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - W Freeman
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M Gabrielyan
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - H R Gallagher
- Department of Physics and Astonomy, Tufts University, Medford, Massachusetts 02155, USA
| | - M Gebhard
- Indiana University, Bloomington, Indiana 47405, USA
| | - T Ghosh
- Instituto de Física, Universidade Federal de Goiás, Goiánia, Goiás 74690-900, Brazil
| | - W Gilbert
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - A Giri
- Department of Physics, IIT Hyderabad, Hyderabad 502 205, India
| | - S Goadhouse
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - R A Gomes
- Instituto de Física, Universidade Federal de Goiás, Goiánia, Goiás 74690-900, Brazil
| | - L Goodenough
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - M C Goodman
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - V Grichine
- Nuclear Physics Department, Lebedev Physical Institute, Leninsky Prospect 53, 119991 Moscow, Russia
| | - N Grossman
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R Group
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Grudzinski
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - V Guarino
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - B Guo
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - A Habig
- Department of Physics and Astronomy, University of Minnesota-Duluth, Duluth, Minnesota 55812, USA
| | - T Handler
- Department of Physics and Astronomy, University of Tennessee, 1408 Circle Drive, Knoxville, Tennessee 37996, USA
| | - J Hartnell
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - R Hatcher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Hatzikoutelis
- Department of Physics and Astronomy, University of Tennessee, 1408 Circle Drive, Knoxville, Tennessee 37996, USA
| | - K Heller
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - C Howcroft
- California Institute of Technology, Pasadena, California 91125, USA
| | - J Huang
- Department of Physics, University of Texas at Austin, 1 University Station C1600, Austin, Texas 78712, USA
| | - X Huang
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - J Hylen
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M Ishitsuka
- Indiana University, Bloomington, Indiana 47405, USA
| | - F Jediny
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - C Jensen
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Jensen
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - C Johnson
- Indiana University, Bloomington, Indiana 47405, USA
| | - H Jostlein
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G K Kafka
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - Y Kamyshkov
- Department of Physics and Astronomy, University of Tennessee, 1408 Circle Drive, Knoxville, Tennessee 37996, USA
| | - S M S Kasahara
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - S Kasetti
- School of Physics, University of Hyderabad, Hyderabad 500 046, India
| | - K Kephart
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G Koizumi
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S Kotelnikov
- Nuclear Physics Department, Lebedev Physical Institute, Leninsky Prospect 53, 119991 Moscow, Russia
| | - I Kourbanis
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - Z Krahn
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - V Kravtsov
- Department of Physics, Southern Methodist University, Dallas, Texas 75275, USA
| | - A Kreymer
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - Ch Kulenberg
- Joint Institute for Nuclear Research Joliot-Curie, 6 Dubna, Moscow Region 141980, Russia
| | - A Kumar
- Department of Physics, Panjab University, Chandigarh 106 014, India
| | - T Kutnink
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - R Kwarciancy
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Kwong
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - K Lang
- Department of Physics, University of Texas at Austin, 1 University Station C1600, Austin, Texas 78712, USA
| | - A Lee
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - W M Lee
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K Lee
- Physics and Astronomy Department, UCLA, Box 951547, Los Angeles, California 90095-1547, USA
| | - S Lein
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - J Liu
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - M Lokajicek
- Institute of Physics, Czech Academy of Sciences, Prague, Czech Republic
| | - J Lozier
- California Institute of Technology, Pasadena, California 91125, USA
| | - Q Lu
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - P Lucas
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S Luchuk
- Institute for Nuclear Research of Russian Academy of Sciences, 7a 60th October Anniversary Prospect, Moscow 117312, Russia
| | - P Lukens
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G Lukhanin
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S Magill
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - K Maan
- Department of Physics, Panjab University, Chandigarh 106 014, India
| | - W A Mann
- Department of Physics and Astonomy, Tufts University, Medford, Massachusetts 02155, USA
| | - M L Marshak
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - M Martens
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Martincik
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - P Mason
- Department of Physics and Astronomy, University of Tennessee, 1408 Circle Drive, Knoxville, Tennessee 37996, USA
| | - K Matera
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M Mathis
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - V Matveev
- Institute for Nuclear Research of Russian Academy of Sciences, 7a 60th October Anniversary Prospect, Moscow 117312, Russia
| | - N Mayer
- Department of Physics and Astonomy, Tufts University, Medford, Massachusetts 02155, USA
| | - E McCluskey
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R Mehdiyev
- Department of Physics, University of Texas at Austin, 1 University Station C1600, Austin, Texas 78712, USA
| | - H Merritt
- Indiana University, Bloomington, Indiana 47405, USA
| | - M D Messier
- Indiana University, Bloomington, Indiana 47405, USA
| | - H Meyer
- Physics Division, Wichita State University, 1845 Fairmout Street, Wichita, Kansas 67220, USA
| | - T Miao
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Michael
- California Institute of Technology, Pasadena, California 91125, USA
| | - S P Mikheyev
- Institute for Nuclear Research of Russian Academy of Sciences, 7a 60th October Anniversary Prospect, Moscow 117312, Russia
| | - W H Miller
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - S R Mishra
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - R Mohanta
- School of Physics, University of Hyderabad, Hyderabad 500 046, India
| | - A Moren
- Department of Physics and Astronomy, University of Minnesota-Duluth, Duluth, Minnesota 55812, USA
| | - L Mualem
- California Institute of Technology, Pasadena, California 91125, USA
| | - M Muether
- Physics Division, Wichita State University, 1845 Fairmout Street, Wichita, Kansas 67220, USA
| | - S Mufson
- Indiana University, Bloomington, Indiana 47405, USA
| | - J Musser
- Indiana University, Bloomington, Indiana 47405, USA
| | - H B Newman
- California Institute of Technology, Pasadena, California 91125, USA
| | - J K Nelson
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - E Niner
- Indiana University, Bloomington, Indiana 47405, USA
| | - A Norman
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Nowak
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - Y Oksuzian
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - A Olshevskiy
- Joint Institute for Nuclear Research Joliot-Curie, 6 Dubna, Moscow Region 141980, Russia
| | - J Oliver
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - T Olson
- Department of Physics and Astonomy, Tufts University, Medford, Massachusetts 02155, USA
| | - J Paley
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - P Pandey
- Department of Physics & Astrophysics, University of Delhi, Delhi 110007, India
| | - A Para
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R B Patterson
- California Institute of Technology, Pasadena, California 91125, USA
| | - G Pawloski
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - N Pearson
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - D Perevalov
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Pershey
- California Institute of Technology, Pasadena, California 91125, USA
| | - E Peterson
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - R Petti
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - S Phan-Budd
- Department of Physics, Winona State University, P.O. Box 5838, Winona, Minnesota 55987, USA
| | - L Piccoli
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - A Pla-Dalmau
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R K Plunkett
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R Poling
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - B Potukuchi
- Department of Physics and Electronics, University of Jammu, Jammu Tawi, 180 006 Jammu & Kashmir, India
| | - F Psihas
- Indiana University, Bloomington, Indiana 47405, USA
| | - D Pushka
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - X Qiu
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - N Raddatz
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - A Radovic
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - R A Rameika
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R Ray
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - B Rebel
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R Rechenmacher
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - B Reed
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - R Reilly
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - D Rocco
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - D Rodkin
- Institute for Nuclear Research of Russian Academy of Sciences, 7a 60th October Anniversary Prospect, Moscow 117312, Russia
| | - K Ruddick
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - R Rusack
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - V Ryabov
- Nuclear Physics Department, Lebedev Physical Institute, Leninsky Prospect 53, 119991 Moscow, Russia
| | - K Sachdev
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - S Sahijpal
- Department of Physics, Panjab University, Chandigarh 106 014, India
| | - H Sahoo
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - O Samoylov
- Joint Institute for Nuclear Research Joliot-Curie, 6 Dubna, Moscow Region 141980, Russia
| | - M C Sanchez
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - N Saoulidou
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - P Schlabach
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - J Schneps
- Department of Physics and Astonomy, Tufts University, Medford, Massachusetts 02155, USA
| | - R Schroeter
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - J Sepulveda-Quiroz
- Argonne National Laboratory, Argonne, Illinois 60439, USA
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - P Shanahan
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - B Sherwood
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - A Sheshukov
- Joint Institute for Nuclear Research Joliot-Curie, 6 Dubna, Moscow Region 141980, Russia
| | - J Singh
- Department of Physics, Panjab University, Chandigarh 106 014, India
| | - V Singh
- Department of Physics, Banaras Hindu University, Varanasi 221 005, India
| | - A Smith
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - D Smith
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - J Smolik
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - N Solomey
- Physics Division, Wichita State University, 1845 Fairmout Street, Wichita, Kansas 67220, USA
| | - A Sotnikov
- Joint Institute for Nuclear Research Joliot-Curie, 6 Dubna, Moscow Region 141980, Russia
| | - A Sousa
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - K Soustruznik
- Charles University in Prague, Faculty of Mathematics and Physics, Institute of Particle and Nuclear Physics, Prague, Czech Republic
| | - Y Stenkin
- Institute for Nuclear Research of Russian Academy of Sciences, 7a 60th October Anniversary Prospect, Moscow 117312, Russia
| | - M Strait
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - L Suter
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - R L Talaga
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - M C Tamsett
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - S Tariq
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - P Tas
- Charles University in Prague, Faculty of Mathematics and Physics, Institute of Particle and Nuclear Physics, Prague, Czech Republic
| | - R J Tesarek
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R B Thayyullathil
- Department of Physics, Cochin University of Science and Technology, Kochi 682 022, India
| | - K Thomsen
- Department of Physics and Astronomy, University of Minnesota-Duluth, Duluth, Minnesota 55812, USA
| | - X Tian
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - S C Tognini
- Instituto de Física, Universidade Federal de Goiás, Goiánia, Goiás 74690-900, Brazil
| | - R Toner
- Department of Physics, Harvard University, Cambridge, Massachusetts 02138, USA
| | - J Trevor
- California Institute of Technology, Pasadena, California 91125, USA
| | - G Tzanakos
- Department of Physics, University of Athens, Athens 15771, Greece
| | - J Urheim
- Indiana University, Bloomington, Indiana 47405, USA
| | - P Vahle
- Department of Physics, College of William & Mary, Williamsburg, Virginia 23187, USA
| | - L Valerio
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - L Vinton
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - T Vrba
- Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic
| | - A V Waldron
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - B Wang
- Department of Physics, Southern Methodist University, Dallas, Texas 75275, USA
| | - Z Wang
- Department of Physics, University of Virginia, Charlottesville, Virginia 22904, USA
| | - A Weber
- Subdepartment of Particle Physics, University of Oxford, Oxford OX1 3RH, United Kingdom
- Rutherford Appleton Laboratory, Science and Technology Facilities Council, Didcot OX11 0QX, United Kingdom
| | - A Wehmann
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | | | - N Wilcer
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - R Wildberger
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - D Wildman
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - K Williams
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S G Wojcicki
- Department of Physics, Stanford University, Stanford, California 94305, USA
| | - K Wood
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - M Xiao
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - T Xin
- Department of Physics and Astronomy, Iowa State University, Ames, Iowa 50011, USA
| | - N Yadav
- Department of Physics, IIT Guwahati, Guwahati 781 039, India
| | - S Yang
- Department of Physics, University of Cincinnati, Cincinnati, Ohio 45221, USA
| | - S Zadorozhnyy
- Institute for Nuclear Research of Russian Academy of Sciences, 7a 60th October Anniversary Prospect, Moscow 117312, Russia
| | - J Zalesak
- Institute of Physics, Czech Academy of Sciences, Prague, Czech Republic
| | - B Zamorano
- Department of Physics and Astronomy, University of Sussex, Falmer, Brighton BN1 9QH, United Kingdom
| | - A Zhao
- Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - J Zirnstein
- School of Physics and Astronomy, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA
| | - R Zwaska
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| |
Collapse
|
18
|
Lin HY, Chin CY, Huang HL, Huang WY, Sie MJ, Huang LH, Lee YH, Lin CH, Lii KH, Bu X, Wang SL. Crystalline Inorganic Frameworks with 56-Ring, 64-Ring, and 72-Ring Channels. Science 2013; 339:811-3. [DOI: 10.1126/science.1232097] [Citation(s) in RCA: 150] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
19
|
Wang W, Lin R, Zhang J, Mao Y, Bu X, Ji Q, Zhai X, Lin Q, Yang L, Zhang K. Involvement of fatty acid metabolism in the hepatotoxicity induced by divalproex sodium. Hum Exp Toxicol 2012; 31:1092-101. [DOI: 10.1177/0960327112444477] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Divalproex sodium is an antiepileptic drug. Hepatotoxicity is one of the most common side effects induced by divalproex sodium. Impaired fatty acid metabolism is considered to play an important role in the drug-induced hepatotoxicity. The sterol regulatory element-binding protein 1c (SREBP-1c) and peroxisome proliferator-activated receptor α (PPARα) are two key transcription factors involved, respectively, in fatty acid synthesis and degradation in liver. In the present study, we investigated the hepatotoxicity induced by divalproex sodium and its potential mechanism. The results indicated that divalproex sodium significantly decreased the cell viability and increased lactate dehydrogenase leakage in hepatocytes. The activities of alanine aminotransferase and aspartate transaminase were increased in hepatocytes treated with divalproex sodium. Furthermore, divalproex sodium activated SREBP-1c and increased the mRNA expressions of acetyl-CoA carboxylase 1, fatty acid synthase and stearoyl-CoA desaturase 1. Divalproex sodium also inhibited PPARα and decreased the messenger RNA expressions of 3-hydroxy-3-methylglutaryl-CoA synthase 2 and carnitine palmitoyltransferase 1A. These results suggest that the hepatotoxicity induced by divalproex sodium may be related with fatty acid synthesis and degradation mediated by SREBP-1c and PPARα in hepatocytes.
Collapse
Affiliation(s)
- W Wang
- Department of Pharmacology, Key Laboratory of Environment and Genes Related to Diseases, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, PR China
| | - R Lin
- Department of Pharmacology, Key Laboratory of Environment and Genes Related to Diseases, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, PR China
| | - J Zhang
- Department of Pharmacology, Key Laboratory of Environment and Genes Related to Diseases, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, PR China
| | - Y Mao
- Shaanxi’s Tiansen Drug Research and Development Limited Company, Xi’an, Shaanxi, PR China
| | - X Bu
- Shaanxi’s Tiansen Drug Research and Development Limited Company, Xi’an, Shaanxi, PR China
| | - Q Ji
- Department of Pharmacology, Key Laboratory of Environment and Genes Related to Diseases, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, PR China
| | - X Zhai
- Shaanxi’s Tiansen Drug Research and Development Limited Company, Xi’an, Shaanxi, PR China
| | - Q Lin
- Department of Pharmacology, Key Laboratory of Environment and Genes Related to Diseases, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, PR China
| | - L Yang
- Department of Pharmacology, Key Laboratory of Environment and Genes Related to Diseases, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, PR China
| | - K Zhang
- Department of Pharmacology, Key Laboratory of Environment and Genes Related to Diseases, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, PR China
| |
Collapse
|
20
|
Abstract
20S-protopanaxadiol (aPPD) is a metabolite of ginseng saponins, which is reported to be pro-apoptotic in some cells but anti-apoptotic in neuronal cells by regulating Akt signaling. Owing to its cholesterol-like structure, we hypothesized that aPPD may regulate Akt signaling by interacting with lipid rafts. Here, we compared Akt signaling in glioblastoma U87MG and neuroblastoma Neuro-2a cells treated with aPPD. aPPD did not change Akt activity in the total plasma membranes of each cell type, but drastically altered the activity of raft-associated Akt. Strikingly, Akt activity was decreased in the rafts of U87MG cells but increased in N2a cells by aPPD through regulating raft-associated dephosphorylation. The bidirectional regulation of raft-associated Akt signaling by aPPD enhanced the chemotoxicity of Paclitaxel or Vinblastine in U87MG cells but attenuated the excitotoxicity of N-methyl--aspartate in N2a cells. Our results demonstrated that the activity of raft-associated but not total membrane Akt determines its cellular functions. Lipid rafts differ in different types of cells, which allows for the possibility of cell-type-specific targeting for which aPPD might prove to be a useful agent.
Collapse
Affiliation(s)
- Y Liu
- Department of Pathology, School of Preclinical Medicine, Beijing University of Chinese Medicine, Chaoyang District, China
| | | | | | | | | | | | | |
Collapse
|
21
|
Bu X, Skrdla P, Dormer P, Bereznitski Y. Separation of triphenyl atropisomers of a pharmaceutical compound on a novel mixed mode stationary phase: A case study involving dynamic chromatography, dynamic NMR and molecular modeling. J Chromatogr A 2010; 1217:7255-64. [DOI: 10.1016/j.chroma.2010.09.042] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2010] [Revised: 09/09/2010] [Accepted: 09/14/2010] [Indexed: 10/19/2022]
|
22
|
Bu X, Zheng Z, Yu Y, Zeng L, Jiang Y. Significance of C4d deposition in the diagnosis of rejection after liver transplantation. Transplant Proc 2006; 38:1418-21. [PMID: 16797320 DOI: 10.1016/j.transproceed.2006.03.018] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2005] [Indexed: 11/19/2022]
Abstract
C4d immunohistochemical staining of liver allograft biopsies was performed to assess its relationship to other pathological changes in the liver. C4d deposition was detected in 69.2% of liver graft biopsies from patients under going rejection, 33.3% of liver graft biopsies from patients with hepatitis B relapse after transplantation, and 28.6% of liver biopsies from patients with hepatitis B. When rejection occurred C4d deposition was located in the vascular walls of portal areas and hepatic sinusoidal walls. Examination of biopsies from patients with hepatitis B relapse after transplantation or hepatitis B infection showed C4d deposition only in the vascular walls of the portal area. C4d deposition in both vascular walls of portal area and hepatic sinusoidal walls was detected in only one of 12 ischemia-reperfusion damage cases. Repeated biopsy of the same patient 1 month later revealed acute cellular rejection. No C4d deposition was found in biopsies from a patient with bile duct occlusion after liver transplantation. C4d might serve as a sensitive marker for the diagnosis of liver rejection.
Collapse
Affiliation(s)
- X Bu
- Department of Pathology, Dongfang Hospitial, Fuzhou, Fujian, China
| | | | | | | | | |
Collapse
|
23
|
Olvera M, Wickramasinghe K, Brynes R, Bu X, Ma Y, Chandrasoma P. Ki67 expression in different epithelial types in columnar lined oesophagus indicates varying levels of expanded and aberrant proliferative patterns. Histopathology 2005; 47:132-40. [PMID: 16045773 DOI: 10.1111/j.1365-2559.2005.02200.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
AIMS To evaluate proliferative patterns in metaplastic columnar epithelia of the oesophagus, classified as oxynto-cardiac (n = 43), cardiac (n = 45) intestinal without dysplasia (n = 41), dysplastic intestinal epithelium (n = 25), and adenocarcinoma (n = 15) by Ki67 immunohistochemistry. METHODS AND RESULTS Abnormal patterns of Ki67 immunoreactivity were classified into (i) expanded proliferation, characterized by increased levels of Ki67 expression in the deep and mid third of the foveolar pit; and (ii) aberrant proliferation, characterized by positive staining in the surface epithelium and superficial third of the foveolar pit. A significant step-wise increase in the frequency of expanded proliferation was seen in oxynto-cardiac, cardiac, intestinal and dysplastic intestinal epithelium indicative of increasing levels of damage. Aberrant proliferation was absent in oxynto-cardiac mucosa, present at a low and similar level in cardiac, intestinal and low-grade dysplastic epithelia and at a significantly increased frequency in high-grade dysplasia. CONCLUSIONS These findings suggest that oxynto-cardiac mucosa occurs in a low damage environment and intestinal metaplasia in a high damage environment along the length of the columnar lined oesophageal segment. Aberrant proliferative patterns with Ki67 staining are not useful in differentiating reactive epithelia from low-grade dysplasia, but may prove useful in the diagnosis of high-grade dysplasia.
Collapse
Affiliation(s)
- M Olvera
- Department of Pathology, Los Angeles County/University of Southern California Medical Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
| | | | | | | | | | | |
Collapse
|
24
|
Yilmaz A, Tatar Yįldįrįm L, Bu X, Kizilyalli M, Stucky GD. New zeotype borophosphates with chiral tetrahedral topology: (H)0.5M1.25(H2O)1.5[BP2O8]·H2O (M = Co(II) and Mn(II)). Cryst Res Technol 2005. [DOI: 10.1002/crat.200410386] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
25
|
Jia W, Yan H, Bu X, Liu G, Zhao Y. Aglycone Protopanaxadiol, a ginseng saponin inhibits P-glycoprotein and sensitizes chemotherapy drugs on multidrug resistant cancer cells. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- W. Jia
- University of British Columbia, Vancouver, BC, Canada; PanaGin Pharmaceuticals, Vancouver, BC, Canada
| | - H. Yan
- University of British Columbia, Vancouver, BC, Canada; PanaGin Pharmaceuticals, Vancouver, BC, Canada
| | - X. Bu
- University of British Columbia, Vancouver, BC, Canada; PanaGin Pharmaceuticals, Vancouver, BC, Canada
| | - G. Liu
- University of British Columbia, Vancouver, BC, Canada; PanaGin Pharmaceuticals, Vancouver, BC, Canada
| | - Y. Zhao
- University of British Columbia, Vancouver, BC, Canada; PanaGin Pharmaceuticals, Vancouver, BC, Canada
| |
Collapse
|
26
|
Yang CT, Song J, Bu X, Cong YS, Bacchetti S, Rennie P, Jia WWG. Herpes simplex virus type-1 infection upregulates cellular promoters and telomerase activity in both tumor and nontumor human cells. Gene Ther 2003; 10:1494-502. [PMID: 12900765 DOI: 10.1038/sj.gt.3302005] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Targeted gene expression through viral vectors has been a promising approach for gene therapy. However, the effects of viral gene products expressed from virus vectors on the expression of the host gene are not well known. In the present study, we examined the activities of cellular promoters, including the promoter for genes of human telomerase reverse transcriptase (hTERT), tyrosinase and probasin, in both tumor and normal cells after infection with herpes simplex virus type 1 (HSV-1) vectors. Our results showed that infection with replication-defective HSV-1 vectors significantly upregulated the activity of all three cellular promoters in a nonsequence specific fashion in all cell types tested. Furthermore, viral infection upregulated activities of the hTERT promoter and endogenous telomerase in nontumoral cells. Additional experiments suggested that the viral immediate-early gene product, infected cell protein 0, might be responsible for the deregulation of cellular promoter activity and activation of telomerase. Our study alerts to the potential risk of oncogenesis through deregulation of host gene expression, such as the telomerase by viral vectors in normal cells.
Collapse
Affiliation(s)
- C-T Yang
- Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan
| | | | | | | | | | | | | |
Collapse
|
27
|
Bu X, Bernstein L, Brynes RK. Reduced risk of synovial sarcoma in females: X-chromosome inactivation? Br J Cancer 2002; 87:28-30. [PMID: 12085251 PMCID: PMC2364289 DOI: 10.1038/sj.bjc.6600362] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2001] [Revised: 04/10/2002] [Accepted: 04/12/2002] [Indexed: 11/09/2022] Open
Abstract
Synovial sarcoma shows a characteristic t(X;18) translocation but not the expected female predominance in incidence. We speculate that, among females, one X-chromosome is inactivated and that only the translocation to an active X-chromosome leads to development of synovial sarcoma. Population-based cancer registry data from the SEER program support this hypothesis.
Collapse
Affiliation(s)
- X Bu
- Department of Pathology, University of Southern California, Keck School of Medicine, Los Angeles, California 90033, USA
| | | | | |
Collapse
|
28
|
Wang C, Li Y, Bu X, Zheng N, Zivkovic O, Yang CS, Feng P. Three-dimensional superlattices built from (M(4)In(16)S(33))(10-)(M = Mn, Co, Zn, Cd) supertetrahedral clusters. J Am Chem Soc 2001; 123:11506-7. [PMID: 11707140 DOI: 10.1021/ja011739r] [Citation(s) in RCA: 97] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- C Wang
- Department of Chemistry, University of California, Riverside, CA 92521, USA
| | | | | | | | | | | | | |
Collapse
|
29
|
Wong BS, Brown DR, Pan T, Whiteman M, Liu T, Bu X, Li R, Gambetti P, Olesik J, Rubenstein R, Sy MS. Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. J Neurochem 2001; 79:689-98. [PMID: 11701772 DOI: 10.1046/j.1471-4159.2001.00625.x] [Citation(s) in RCA: 110] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Prion diseases are characterized by the conversion of the normal cellular prion protein (PrP(C)) into a pathogenic isoform (PrP(Sc)). PrP(C) binds copper, has superoxide dismutase (SOD)-like activity in vitro, and its expression aids in the cellular response to oxidative stress. However, the interplay between PrPs (PrP(C), PrP(Sc) and possibly other abnormal species), copper, anti-oxidation activity and pathogenesis of prion diseases remain unclear. In this study, we reported dramatic depression of SOD-like activity by the affinity-purified PrPs from scrapie-infected brains, and together with significant reduction of Cu/Zn-SOD activity, correlates with significant perturbations in the divalent metals contents. We also detected elevated levels of nitric oxide and superoxide in the infected brains, which could be escalating the oxidative modification of cellular proteins, reducing gluathione peroxidase activity and increasing the levels of lipid peroxidation markers. Taken together, our results suggest that brain metal imbalances, especially copper, in scrapie infection is likely to affect the anti-oxidation functions of PrP and SODs, which, together with other cellular dysfunctions, predispose the brains to oxidative impairment and eventual degeneration. To our knowledge, this is the first study documenting a physiological connection between brain metals imbalances, the anti-oxidation function of PrP, and aberrations in the cellular responses to oxidative stress, in scrapie infection.
Collapse
Affiliation(s)
- B S Wong
- Institute of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Affiliation(s)
- P Feng
- Chemistry Department, University of California, Riverside, 92521, USA
| | | | | |
Collapse
|
31
|
Liu Z, Bu X, Xing G, Lu L. [A preliminary study of a hearing screening model for newborn]. Zhonghua Er Bi Yan Hou Ke Za Zhi 2001; 36:292-4. [PMID: 12762000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
OBJECTIVE To search for a hearing screening model for newborn and to investigate the prevalence of newborn hearing loss in our country. METHODS The distortion product otoacoustic emissions (DPOAE) was used to test the hearing in 2,998 of 3,075 newborns before discharge. Otoacoustic emissions (OAE) was again used for cases failed in the hospital screening 4 weeks later. Those cases failed in both screening steps were finally tested by auditory brainstem response (ABR). All infants failed in ABR test received diagnostic evaluation audiologically to identify the category and degree of hearing loss. The pass criterion of DPOAE was defined as signal-noise-ratio (SNR) exceeding 6 dB in 4 of 5 frequencies between 1.5-6 kHz. The pass criterion of ABR was the presence of wave V in response to 35 dB nHL click stimuli. RESULTS The OAE screening in the hospital showed that 2,710 (90.4%) newborns passed the first test. Two hundred and sixty three of 288 newborns passed the second OAE screening after one month. Six of 25 infants failed in ABR test were eventually identified to be hearing impaired. CONCLUSION Two-stages screening, combining OAE and ABR tests, may be an ideal model for newborn hearing screening. The prevalence of congenital hearing loss is similar to that reported in the literature.
Collapse
Affiliation(s)
- Z Liu
- Department of Otorhinolaryngology, First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
| | | | | | | |
Collapse
|
32
|
Tang Y, Bu X, Yao Q, Xie Q, Qian M, Hu Y, Yu Y. [Audiological findings of the aging across the urban and rural of Suzhou]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2001; 15:315-7. [PMID: 12541792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
OBJECTIVE To determine the epidemiological characteristics of old people's hearing. METHOD Questionnaires, physical examination, audiometry and bio-chemical tests were performed on the elders above 60 years old in part of the urban and rural area of Suzhou with random sample survey. RESULT A total of 1,040 individuals was investigated, among which 505 were from urban, and 535 were from rural. 33 of 505 senior citizen (6.53%) were nososacusis, 282 (55.84%) were presbycusis and 21 (4.16%) were noise-induced deafness; In the rural area, 35 of 535 (6.54%) were nososacusis, 232 (43.36%) were presbycusis, and 4 (0.75%) were noise deafness. There was significant difference of the incidence of presbycusis between urban and rural. The audiometric thresholds chart manifested that the threshold elevated with age increasing especially in high-frequency. CONCLUSION The etiology of hearing loss of elders was mainly due to presbycusis. The higher incidence of psychotic disorder in urban probably caused a correspondingly higher incidence of presbycusis. So the prevention and cure of some age-induced diseased (e.g. hypertension, arteriosclerosis and diabetes) may be helpful to release and improve presbycusis.
Collapse
Affiliation(s)
- Y Tang
- Department of Otolaryngology, First Affiliated Hospital of Suzhou University, Suzhou 215006
| | | | | | | | | | | | | |
Collapse
|
33
|
Bu X, Deady LW, Finlay GJ, Baguley BC, Denny WA. Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives. J Med Chem 2001; 44:2004-14. [PMID: 11384245 DOI: 10.1021/jm010041l] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A series of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidines bearing cationic side chains were prepared from aminoanthraquinones. The perimidines were prepared from 1-aminoanthraquinone by initial condensation with urea or dimethylacetamide. A series of 2-, 4-, 8-, and 11-carboxy derivatives of the dibenzisoquinolines were prepared from aminoanthraquinonecarboxylic acids. The cationic derivatives were prepared from these via amide, amine, or methylene linkers to study the effects of side chain positioning on biological activity. Within the series of carboxamide-linked compounds, the order of increasing cytotoxicity was 8- < 4- < 2- < 11-. The 2- and 4-carboxamides showed substantial growth delays against in vivo subcutaneous colon 38 tumors in mice, but the 11-carboxamide had curative activity in this refractory model and is being investigated further.
Collapse
Affiliation(s)
- X Bu
- Chemistry Department, La Trobe University, Bundoora, Victoria 3083, Australia
| | | | | | | | | |
Collapse
|
34
|
Affiliation(s)
- B Y Lee
- Departments of Chemistry and Materials University of California, Santa Barbara, California 93106, USA
| | | | | | | | | |
Collapse
|
35
|
Zhen H, Zhang X, Bu X. [Formation of specific complex of SV40 large tumor antigen and p53 in human brain tumors]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2001; 15:73-6. [PMID: 12526309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
OBJECTIVE To study the interaction of SV40 early region gene coding product, the large tumor antigen(Tag) with tumor suppressor p53 in human brain tumorigenesis. METHODS Tag was detected by immunoprecipitation and Western blot in 43 cases of human brain tumors and 5 cases of normal human brain tissues. Tag-p53 specific complex was screened in 18 Tag positive cases. RESULTS Tag was found in all of 5 ependymomas and 2 choroid plexus papillomas, as well as in pituitary adenomas (5/6), astrocytomas (7/10), meningiomas (4/6), glioblastomas multiforme (3/5) and medulloblastomas (2/5). None of the 5 normal brain tissues were positive for Tag, nor were 3 oligodendrogliomas and 1 pineocytoma. Tag-p53 complexes were found in all of 18 Tag positive cases. CONCLUSION SV40 Tag can form a specific complex with p53 in human brain tumors, the inactivation of p53 due to the formation of Tag-p53 complex may be one of the important mechanisms of human brain tumorigenesis.
Collapse
Affiliation(s)
- H Zhen
- Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China
| | | | | |
Collapse
|
36
|
Xing G, Chen Z, Bu X. [Diagnosis and treatment of horizontal canal benign paroxysmal positional vertigo]. Zhonghua Er Bi Yan Hou Ke Za Zhi 2001; 36:28-30. [PMID: 12761903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
OBJECTIVE To explore effective methods for the diagnosis and treatment of horizontal-canal benign paroxysmal positional vertigo (HC-BPPV). METHODS Medical records from nine patients with HC-BPPV, treated between July 1996 and March 2000, were retrospectively analyzed. Data of complete history, audiograms, positional tests and neuro-otological examinations were collected. All patients were treated with a particle repositioning maneuver called the "barbecue rotation" which starts with the patient in the supine position and consists of three 90-degree head rotations towards the unaffected ear. RESULTS HC-BPPV was characterized by brief attacks of intense vertigo that were induced mainly by rolling over in bed (9/9) and turning the head to either side while upright (5/9). In most cases, rotation to the pathological side from supine position caused a very intense horizontal nystagmus beating towards the undermost ear. Findings such as latency and fatigability, which are common features of posterior-canal BPPV (PC-BPPV), were not present. After the barbecue rotation, all patients had immediate and sustained relief of their attacks during the 4 to 15 months' follow up. CONCLUSION HC-BPPV is different from PC-BPPV and other vertiginous diseases in typical presentations and positional testing results. The barbecue rotation is a successful method for curing the disorder.
Collapse
Affiliation(s)
- G Xing
- Department of Otorhinolaryngology, First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
| | | | | |
Collapse
|
37
|
Xing G, Yan M, Bu X. [Whole genome-wide scanning for a large pedigree with matrilineal deafness]. Zhonghua Er Bi Yan Hou Ke Za Zhi 2000; 35:413-5. [PMID: 12768748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
OBJECTIVE To search responsible nuclear genes for matrilineal non-syndromic deafness. METHODS Whole genome-wide scanning was performed to analyze the 365 short tandem repeats in a deaf pedigree with maternal inheritance using DNA pooling strategy. Frequencies of allele in one patient pool were compared with that in one unaffected relative pool as well as in one normal control pool. Linkage analysis was also conducted in some positive loci. RESULTS Allele from 45 loci occurred more frequently in the patient pool than that in the unaffected relative pool and the control pool. No linkage was found from any candidate locus investigated. CONCLUSION 45 positive loci obtained from this family may be as the candidate positions for matrilineal non-syndromic deafness.
Collapse
Affiliation(s)
- G Xing
- Department of Otorhinolaryngology, First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China.
| | | | | |
Collapse
|
38
|
Zhang X, Bu X, Zhen H, Fei Z, Wu J, Gu J, Yi S, Wang Z. Expression and significance of urokinase-type plasminogen activator in human gliomas. Chin Med J (Engl) 2000; 113:802-4. [PMID: 11776074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023] Open
Abstract
OBJECTIVE To investigate the expression and clinical significance of urokinase type plasminogen activator (uPA) in human gliomas. METHODS mRNA and protein expressions of uPA were examined by Northern blot hybridization and immunohistochemical method in 43 cases of gliomas and 5 cases of normal brain tissues and their relationship to clinical indexes was comprehensively analyzed. RESULTS All tissues expressed the 2.5 kb transcript of uPA mRNA. The uPA mRNA level in high-grade gliomas was considerably higher than that in low-grade gliomas and normal brain tissues (P < 0.01). Levels of uPA mRNA expression in tumor tissues with recurrence during 18 postoperative months and a survival period less than 3 years, were significantly higher than counterparts (P < 0.01). uPA mRNA expression was strongly correlated with the microvessel quantity (MVQ) in gliomas (r = 0.56, P < 0.01). uPA protein was mainly distributed in tumor cells and endothelial cells of glioblastomas and anaplastic astrocytomas. CONCLUSION Expression of uPA is associated with the malignant progression, invasion and angiogenesis of gliomas, and it may play a critical role in the recurrence and prognosis of gliomas.
Collapse
Affiliation(s)
- X Zhang
- Department of Neurosurgery, Xi-Jing Hospital, Fourth Military Medical University, Xi'an 710032, China.
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Geurts JM, Janssen RG, van Greevenbroek MM, van der Kallen CJ, Cantor RM, Bu X, Aouizerat BE, Allayee H, Rotter JI, de Bruin TW. Identification of TNFRSF1B as a novel modifier gene in familial combined hyperlipidemia. Hum Mol Genet 2000; 9:2067-74. [PMID: 10958645 DOI: 10.1093/hmg/9.14.2067] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Familial combined hyperlipidemia (FCHL) is the most commonly inherited hyperlipidemia in man, with a frequency of +/-1% in the general population and approximately 10% in myocardial infarction survivors. A genomic scan in 18 Dutch FCHL families resulted in the identification of several loci with evidence for linkage. One of these regions, 1p36.2, contains TNFRSF1B which encodes one of the tumor necrosis factor receptors. An intron 4 polymorphic CA-repeat was used to confirm linkage to FCHL. Linear regression analysis using 79 independent sib pairs showed linkage with a quantitative FCHL discriminant function (P = 0.032), and, borderline, with apolipoprotein B levels (P = 0.064). Furthermore, in a case-control study, association was demonstrated since the overall CA-repeat genotype distribution was significantly different among 40 unrelated FCHL patients and 48 unrelated healthy spouse controls (P = 0.029). This difference was due to a significant increase in allele CA271 homozygotes in the FCHL patients (P = 0.019). Mutation analysis of exon 6 in 73 FCHL family members demonstrated the presence of a single nucleotide polymorphism with two alleles, coding for methionine (196M) and arginine (196R). Complete linkage disequilibrium between CA267, CA271 and CA273 and this polymorphism was detected. In 85 hyperlipidemic FCHL subjects, an association was demonstrated between soluble TNFRSF1B plasma concentrations and the CA271-196M haplotype. In conclusion, TNFRSF1B was found to be associated with susceptibility to FCHL. Our data suggest that an as yet unknown disease-associated mutation, linked to alleles 196M and CA271, plays a role in the pathophysiology of FCHL.
Collapse
Affiliation(s)
- J M Geurts
- Laboratory of Molecular Metabolism and Endocrinology, Department of Internal Medicine, Cardiovascular Research Institute Maastricht, Academic Hospital, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Lee A, DeJong G, Guo J, Bu X, Jia WW. Bax expressed from a herpes viral vector enhances the efficacy of N,N'-bis(2-hydroxyethyl)-N-nitrosourea treatment in a rat glioma model. Cancer Gene Ther 2000; 7:1113-9. [PMID: 10975671 DOI: 10.1038/sj.cgt.7700205] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
N,N'-bis(2-hydroxyethyl)-N-nitrosourea (BCNU) is a commonly used agent for treatment of malignant gliomas. The mechanisms of cell death and the role of Bcl-2 and Bax in a BCNU-treated rat glioma cell line were investigated. Our results indicate that apoptosis occurs only at a high concentration of BCNU with elevated levels of Bax and a reversed ratio of Bax/Bcl-2. Overexpression of Bax delivered by a herpes simplex viral vector in combination with BCNU chemotherapy enhanced the efficacy of BCNU in a rat glioma model. These findings suggest that conventional treatment with BCNU may be combined with gene therapy that delivers a bax gene into the glioma cells to achieve a high level of Bax, facilitating BCNU-induced cytotoxicity.
Collapse
Affiliation(s)
- A Lee
- Department of Surgery, University of British Columbia, Vancouver, Canada
| | | | | | | | | |
Collapse
|
41
|
Yen H, Florentine B, Kelly LK, Bu X, Crawford J, Martin SE. Fine-needle aspiration of a metaplastic breast carcinoma with extensive melanocytic differentiation: a case report. Diagn Cytopathol 2000; 23:46-50. [PMID: 10907933 DOI: 10.1002/1097-0339(200007)23:1<46::aid-dc11>3.0.co;2-f] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Metaplastic carcinomas of the breast are uncommon breast tumors with aberrant cellular differentiation, most commonly showing ductal, squamous, and mesenchymal components. A breast carcinoma composed of both epithelial and melanocytic differentiation is rare, with only four previously reported cases in the literature. We present the fifth reported case, where the diagnosis was suggested by fine-needle aspiration (FNA) and later confirmed after the surgical specimen was excised. Histologically, this neoplasm revealed multidirectional differentiation, consisting primarily of squamous and melanocytic cell types, with focal glandular and osseous metaplasia. Based on the morphologic, immunohistochemical, and ultrastructural findings, we conclude that such tumors fall within the spectrum of metaplastic carcinomas of the breast. We believe that this case will further contribute to the understanding of this enigmatic tumor.
Collapse
MESH Headings
- Antigens, Neoplasm
- Biopsy, Needle
- Breast/chemistry
- Breast/pathology
- Breast/ultrastructure
- Breast Neoplasms/chemistry
- Breast Neoplasms/diagnosis
- Breast Neoplasms/pathology
- Breast Neoplasms/surgery
- Carcinoma, Adenosquamous/chemistry
- Carcinoma, Adenosquamous/diagnosis
- Carcinoma, Adenosquamous/pathology
- Carcinoma, Adenosquamous/surgery
- Carcinoma, Ductal, Breast/chemistry
- Carcinoma, Ductal, Breast/diagnosis
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Ductal, Breast/surgery
- Cell Differentiation
- Female
- Humans
- Immunohistochemistry/methods
- Lymphatic Metastasis
- Mastectomy, Modified Radical
- Melanocytes/chemistry
- Melanocytes/cytology
- Melanoma/diagnosis
- Melanoma/pathology
- Melanoma-Specific Antigens
- Melanosomes
- Microscopy, Electron/methods
- Middle Aged
- Neoplasm Proteins/analysis
- S100 Proteins/analysis
Collapse
Affiliation(s)
- H Yen
- Department of Pathology, Los Angeles County and University of Southern California Healthcare Network, University of Southern California School of Medicine, 90033, USA
| | | | | | | | | | | |
Collapse
|
42
|
Abstract
BACKGROUND AND OBJECTIVES Urokinase type plasminogen activator (uPA) regulates a variety of processes involved in tissue morphogenesis, cell differentiation, migration and invasion. We analyzed the available informations to better interpret the pathogenetic relationship between uPA activity and the malignant biological behavior of human brain gliomas. METHODS We retrospectively studied the presence and distribution of uPA in human brain gliomas by Northern blot hybridization and immunohistochemical methods in 43 cases of brain gliomas and 5 cases of normal brain tissues. RESULTS All tissues expressed 2.5 kb transcripts of uPA mRNA. The uPA mRNA levels were significantly higher in high-grade gliomas than in low-grade gliomas and normal brain tissues (P < 0.01). Levels of uPA mRNA expression in tumor tissues with recurrence in 18 months postoperatively and survival period less than 3 years were significantly higher than counterparts (P < 0.01). The distribution of uPA protein in the immunoreactivity was mainly in tumor cells and microvascular endothelial cells of glioblastomas and anaplastic astrocytomas, localizing at cytoplasms, especially near sites of vascular proliferation and at the leading edges of tumors. CONCLUSIONS High expression of uPA gene is associated with the malignant progression of gliomas and demonstrates a high level of correlation with the recurrence and invasive behaviors of high grade gliomas.
Collapse
Affiliation(s)
- X Zhang
- Neurosurgical Research Institute, Xi-Jing Hospital, The Fourth Military Medical University, Xian, PR China.
| | | | | | | | | | | | | |
Collapse
|
43
|
Xing G, Bu X, Yan M, Lu L, Yang S. [Audiological findings and mitochondrial DNA mutation in a large family with matrilineal sensorineural hearing loss]. Zhonghua Er Bi Yan Hou Ke Za Zhi 2000; 35:98-101. [PMID: 12768662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
OBJECTIVE To explore audiological features of matrilineal non-syndromic deafness and its molecular mechanism. METHODS A large family with 41 members having inherited deafness was studied. Complete history and the data of general and otolaryngological examinations were collected. All subjects were screened for mitochondrial DNA A1555G mutation by molecular analysis. Audiological evaluation included puretone audiometry, auditory brainstem responses and transiently evoked otoacoustic emissions. RESULTS All subjects were in good health generally. Molecular analysis showed that all maternal relatives with or without hearing loss harbored the A1555G mitochondrial mutation. No mutation was found among spouses and paternal relatives. Audiological results showed notable symmetric bilateral sensorineural hearing loss in 17 of 20 maternal relatives, in which 5 cases had a progressive hearing loss in the recent 11 years. The age of appearance of hearing loss ranged from 1 to 50 years. CONCLUSION All hearing-impaired subjects of this family had late-onset sensorineural hearing loss. Most of which were progressive. The A1555G mitochondrial mutation in the 12S rRNA gene is responsible for the disorder. Other factors, such as nuclear genes or environmental determinants, may influence the clinical expression of mutant mtDNA.
Collapse
Affiliation(s)
- G Xing
- Department of Otorhinolaryngology, First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
| | | | | | | | | |
Collapse
|
44
|
Bu X, Xiao G, Gu L, Zhang M. [Chemical study of Alpinia officinarum]. Zhong Yao Cai 2000; 23:84-7. [PMID: 12575143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
Seven compounds were isolated from Alinia officinarum Hance and were identified as beta-sitoterol, 1,7-diphenyl-5-ol-3-heptone, 1-phenyl-7-(3'-methoxyl-4'-hydroxyl) phenyl-5-ol-3-heptone, glandin, kaempferol-4'-methylether and 3,4-dihydroxylbenzoic acid by IR, 1HNMR, 13CNMR, FAB-MS and EA. Among these compounds, 3,4-dihydroxylbenzoic acid was the first time obtained from Alpinia officinarum Hance. Furthermore, 1-phenyl-7-(3'-methoxyl-4'-hydroxyl) phenyl-5-ol-3-heptone and a new compound 1,7-diphenyl-3,5-heptandiol-phenyl-7-(3'-methoxyl-4'-hydroxyl) phenyl-3,5-heptaxdiol were obtained from 1,7-diphenyl-5-ol-3-heptone and 1-phenyl-7-(3'-methoxyl-4'-hydroxyl) phenyl-5-ol-3-heptone via chemical reductions.
Collapse
Affiliation(s)
- X Bu
- Zhongshan University, Guangzhou 510275
| | | | | | | |
Collapse
|
45
|
Bu X, Zhang X, Zhang X, Yi S. [A study of simian virus 40 infection and its origin in human brain tumors]. Zhonghua Liu Xing Bing Xue Za Zhi 2000; 21:19-21. [PMID: 11860751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
OBJECTIVE To study the status of simian virus 40 (SV40) infection and its origin in human brain tumors. METHODS Polymerase chain reaction (PCR) and Dot blot hybridization were used to detect SV40 DNA sequences in 516 human brain tumor tissues, 80 peripheral blood cells and 50 sperm fluids from healthy individuals, 100 human embryo tissues from artificial abortion, 30 normal brain tissues and two human glioma cell lines: SHG44 and BT325. RESULTS SV40 DNA sequences were found in 36.4% of human brain tumors (188/516), 16.3% of healthy peripheral blood cells (13/80), 22.0% of healthy semen (11/50), 8.0% of human embryo tissues (8/100) and 6.7% of normal brain tissues (2/30). SV40 DNA sequences were also detected in SHG44 and BT325 cell lines. The positive rates of SV40 DNA in human brain tumors, peripheral blood cells and semen from healthy donors were significantly higher than those in human normal brain and embryo tissues (P < 0.05). CONCLUSIONS (1) SV40 has a higher infection rate in human brain tumors, (2) SV40 is closely related to the etiopathogenesis of human brain tumors, (3) the ways of SV40 spread may due to both horizontal and diaplacental infections in human population.
Collapse
Affiliation(s)
- X Bu
- Department of Neurosurgery, Henan Provincial People's Hospital, Zhengzhou 450003, China
| | | | | | | |
Collapse
|
46
|
Feng P, Bu X, Stucky GD. Control of structural ordering in crystalline lamellar aluminophosphates with periodicity from 51 to 62 A. Inorg Chem 2000; 39:2-3. [PMID: 11229025 DOI: 10.1021/ic991026y] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- P Feng
- Department of Chemistry, University of California, Santa Barbara, California 93106, USA
| | | | | |
Collapse
|
47
|
Abstract
The fluorescent characteristics of Troger's base have been investigated experimentally. A one-photon-induced fluorescent spectrum was observed, and the peak wavelength was at 337 nm with a full width at half-maximum of ~85nm . The violet radiation of the Troger's base crystal could result from the pi(*) -pi transition of the benzenoid pi bond. Two-photon-pumped frequency-upconverted fluorescence was obtained, which is a wideband emission with the main peak wavelength at 337 nm and a subordinate peak. Donor groups and acceptor groups of electrons in the aromatic rings strengthen the two-photon-pumped frequency-upconverted fluorescence.
Collapse
|
48
|
Abstract
Herbal medicines are increasingly being utilized to treat a wide variety of disease processes. Gypenosides are triterpenoid saponins contained in an extract from Gynostemma pentaphyllum and are reported to be effective in the treatment of cardiovascular diseases; however, the mechanism underlying the therapeutic effect is not known. We tested the hypothesis that gypenosides extracted from G. pentaphyllum elicit vasorelaxation through the direct release of endothelium-derived nitric oxide. Nitric oxide production in bovine aortic endothelial cells grown under standard tissue culture conditions was quantitated using a chemiluminescence method. Arterial vasomotion was assayed using isolated porcine coronary artery rings under standard isometric recording conditions. The extract of G. pentaphyllum at 0.1-100 microg/ml elicited concentration-dependent vasorelaxation of porcine coronary rings that was antagonized by the nitric oxide synthase inhibitor N(G)-nitro-l-arginine methyl ester. Indomethacin had no significant effect on G. pentaphyllum-induced relaxation. The G. pentaphyllum extract elicited a concentration-dependent increase in nitric oxide production from cultured bovine aortic endothelial cells. At the concentrations utilized, there was no morphological evidence for cellular toxicity. These results demonstrate that extracts of G. pentaphyllum directly stimulate nitric oxide release, but not prostanoid production. Nitric oxide production in response to gypenosides may be one mechanism whereby this herbal medicine elicits its therapeutic effects.
Collapse
Affiliation(s)
- M A Tanner
- Division of Cardiology, Vanderbilt University Medical Center and the Department of Veterans Affairs Hospital, Nashville, Tennessee, 37232-6300, USA
| | | | | | | |
Collapse
|
49
|
Xing G, Bu X. [Particle repositioning maneuver for benign paroxysmal positional vertigo of posterior semicircular canal]. Zhonghua Er Bi Yan Hou Ke Za Zhi 1999; 34:163-5. [PMID: 12764809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
OBJECTIVE To determine the effectiveness of particle repositioning maneuver (PRM) for the treatment of benign paroxysmal positional vertigo (BPPV). METHODS Thirty one patients with BPPV of the posterior semicircular canal treated between July 1996 and June 1998 were retrospectively analyzed. Patients received a single treatment of PRM based on the hypothesis that the vertigo and nystagmus of BPPV were due to debris floating in the long arm of the posterior canal (canalithiasis). Treatment outcome was classified as cure (asymptomatic), improvement reduction of symptoms > 50%, or no change. RESULTS After a single treatment of PRM, complete remission of vertigo and nystagmus were found in 67.7% of the patients and improvement of the symptoms was found in 19.4% of the patients. The total improvement rate was 87.1%. CONCLUSION The particle repositioning maneuver was effective for most of the patients with benign paroxysmal positional vertigo and can be recommended as the first-line treatment modality.
Collapse
Affiliation(s)
- G Xing
- Department of Otorhinolaryngology, First Affiliated Hospital, Nanjing Medical University, Nanjing 210029
| | | |
Collapse
|
50
|
Bu W, Ye L, Xu Q, Bu X, Yang G, Fan Y. Bis(μ-azido-κ N1:κ N1)bis{[2-(1,5-diazacyclooct-1-yl-κ 2N, N'-methyl)phenolato-κ O]copper(II)}. Acta Crystallogr C 1999. [DOI: 10.1107/s0108270199099515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|